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SUMMARY
In the present study, human hybridoma techniques were 
employed to study autoreactive lymphocytes present in the 
peripheral blood of a patient with acute onset Type 1 
(insulin-dependent) diabetes mellitus. Peripheral blood 
lymphocytes from this patient were fused with mouse myeloma 
NSl cells. Resulting hybridomas were selected by their 
growth in HAT medium. Hybridomas secreting human
immunoglobulins were identified by a two-site
immunoradiometric assay. After cloning and expansion in 
tissue culture, nineteen cell lines were obtained that 
secreted human immunoglobulin.
Two cell lines, HML3.21 and HML3.22 were characterized. 
Karyotype analysis confirmed that the cell lines were human- 
mouse heterohybridomas. Immunodiffusion, immunofixation, and 
SDS-PAGE studies showed that the two monoclonal antibodies 
were human IgG (k-light chain) class. Immunohistoe hemistry 
and thyroid assays indicated that HML3.21 identified 
thyroglobulin, while HML3.22 recognized an epitope on the TSH 
receptor. The study demonstrated the potential usefulness of 
human monoclonal antibodies as tools to study autoimmunity in 
Type 1 diabetes mellitus.
Two assays were developed for the detection of islet 
cell surface antibodies (ICSA). Both assay systems employed 
the rat insulin-secreting line RINmSF. Optimization and 
validation studies were performed. The cell
immunoradiometric assay (IRMA) could be performed with a 60 
minute incubation of sample followed by a 60 minute
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incubation with radiolabelled second antibody. A rapid ELISA 
■for islet cell surface antibodies was developed. Sera from 
Type 1 diabetic patients were incubated for 30 minutes with 
RINmSF cell membrane antigens pre-coated onto microtitre 
wells. Bound immunoglobulins were detected by a further 
incubation with an enzyme-labelled second antibody for 30 
minutes. No significant cross-reactivity was observed in the 
assay for other autoantibodies. There was good correlation 
between the two assay systems.
page II
To; Dad and Mum 
for their love and friendship
page III
ACKNOWLEDGEMENTS
I wish to thank Dr. Kim Tan and Professor Vincent Marks 
for their constant interest, and encouragement 
throughout the course of this project. I have
especially enjoyed the collaboration, and the many
stimulating discussions that have arisen throughout the 
project. My thanks are also due to Drs. Peter Flatt and 
John Wright for their help and advice at various stages 
of the work. I am grateful to Mr. Tony Medlen from the 
Department of Microbiology, for all his help with tissue 
culture techniques. I would also like to thank all my 
colleagues in the Division of Clinical Biochemistry, who 
have made working in the department a rewarding
experience.
page IV
CONTENTS Page
Summary I
Ded ication III
Acknowledgements IV
CHAPTER ONE: GENERAL INTRODUCTION 1
1.1 AUTOIMMUNITY IN DIABETES MELLITUS 2
1.1.1 Evidence that Type 1 diabetes 3 
is an autoimmune disease
1.1.2 Diabetes and Autoimmunity to 5 
Endocrine tissues
1.1.3 Insulitis 8
1.1.4 Genetic -factors and Type 1 IDDM 9
1.1.5 Islet Cell Antibodies 11
a) Islet cell cytoplasmic autoantibodies 12
b) Islet cell surface autoantibodies 14
1.1.6 Possible Mechanisms of Autoimmune 18 
B-cell destruction
1.1.7 Significance of Multiple Tissue 21 
Auto i mmun i ty
1.2 MONOCLONAL ANTIBODIES AND THE STUDY 23 
OF AUTOIMMUNITY
1.2.1 Monoclonal Antibodies and SLE 25
1.2.2 Rodent Monoclonal Antibodies and ICA 26
page V
CHAPTER TWO: PRODUCTION OF HUMAN MONOCLONAL 28
ANTIBODIES FROM A DIABETIC PATIENT
2.1 INTRODUCTION 29
2.1.1 Applications of Human Monoclonal Antibodies 29
2.1.2 Production of Human Monoclonal Antibodies 31
2.1.3 Human Monoclonal Antibodies and the Study 35
of Autoimmunity
2.1.4 Human Monoclonal Islet Cell Antibodies 36
2.1.5 Autoantibodies in Graves disease 37
2.1.6 P o 1yendocrine Autoimmunity 39
2.2 METHODOLOGY 41
2.2.1 Preparation of Human Hybridomas 41
2.2.2 Immunoradiometric assays 47 
for Human IgG and IgM
2.2.3 Karyotyping of Cell Lines 51
2.2.4 CAM Techniques 53
A) Ouchterlony Precipitin Technique 54
B ) Immunofixation Electrophoresis 55
2.2.5 SDS-Po1yacry 1 amide Gel Electrophoresis 56
2.2.6 Immunohistochemistry 60
2.2.7 i==I-Uptake Studies in FRTL-5 Cells 63
2.2.8 TSH Receptor Antibody Assay 66
2.3 RESULTS 67
2.3.1 Human IgG and IgM Assays 67
2.3.2 Heterohybridoma Production 67
2.3.3 Karyotyping Study 73
2.3.4 Immunodiffusion Study 76
2.3.5 Immunofixation Study 76
2.3.6 SDS-PAGE 79
2.3.7 Immunohistochemistry 79
page VI
2.3.8 ^ '^“^ 1-Uptake Studies on HML3.2.2 84
2.3.9 TSH Receptor Antibody Assay 84
2.4 DISCUSSION 89
CHAPTER THREE: DEVELOPMENT OF IMMUNOASSAYS FOR 96
ISLET CELL SURFACE ANTIBODIES
3.1 INTRODUCTION 97
3.1.1 Insulin-Secreting Rat Cell Line RINmSF 100
3.1.2 Immunoassays for ICSA 102
3.2 METHODOLOGY 104
3.2.1 Cell Immunoradiometric Assay 109
3.2.2 Enzyme-Linked Immunosorbent Assay 113
3.3 RESULTS 121
3.3. 1 Cel 1 IRMA 121
3.3.2 ELISA 128
3.4 DISCUSSION 139
CHAPTER FOUR: FINAL DISCUSSION AND CONCLUSIONS 143
REFERENCES 152
LIST OF PUBLICATIONS 179
page VII
CHAPTER ONE
GENERAL INTRODUCTION
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CHAPTER 1: GENERAL INTRODUCTION
1.1 AUTOIMMUNITY IN DIABETES MELLITUS
Diabetes mellitus is a group of disorders that is
characterized clinically by polyuria and polydipsia, and
biochemically by hyperg 1ycaemia and glycosuria. It is
currently classified into two major syndromes, 
insulin-dependent diabetes mellitus (IDDM or Type 1 diabetes) 
and non-insulin-dependent diabetes mellitus (NIDDM or Type 2 
diabetes), (WHO Classification, 1980; National Diabetes Data 
Group, 1979). It is believed that these two main syndromes 
may be distinguished by some characteristic features.
Type 1 (insulin-dependent) diabetes mellitus, usually 
appears in childhood, but can occur at any age. It is 
usually characterized by the abrupt onset of symptoms, 
insu1inopenia, proneness to ketoacidosis, and dependence on 
injected insulin to prevent ketosis and to sustain life. It
is believed that genetic determinants are important in the
disorder since there is an association with certain
histocompatibility antigens (HLA). Autoimmune abnormalities, 
including the appearance of islet cell antibodies are 
associated with the disorder. Over the last decade much 
evidence of this kind has accumulated to suggest that 
autoimmune mechanisms are involved in the specific 
destruction of pancreatic B-cells, preceding the clinical 
onset of insulin-dependent diabetes mellitus. It is this 
immunological aspect of Type 1 diabetes mellitus that has
been of great interest. There is also evidence of a viral
aetiology for some cases.
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Type 2 (non-insulin-dependent) diabetes mellitus is the 
term used to describe subjects who are not insulin-dependent 
or ketosis-prone, although insulin may be required to correct 
any episodes of hyperglycaemia. Subjects may develop ketosis 
under certain circumstances, such as with an infection or 
other stress. Most of the subjects with NIDDM are adults at 
the time of onset, and are usually obese. There is a strong 
familial pattern in Type 2 diabetes, and twin studies provide 
evidence of a strong genetic basis. Obesity is not always 
present but is thought to be an important factor in the
aetiology of the disorder for some patients. Type 2 diabetes 
does not display an association with histocompatibility 
markers, and does not appear to involve the same kind of 
autoimmune phenomena that are associated with Type 1
diabetes. Nevertheless, the typical vascular complications 
such as retinopathy, nephropathy, peripheral vascular 
disease, and increased frequency of coronary disease seen in
Type 1 diabetes also frequently develop in Type 2 diabetic
patients.
1.1.1 Evidence that Type 1 diabetes is an autoimmune 
d i sease
There are a number of human diseases that involve 
antibodies (called autoantibodies) which have reacted in a 
damaging way against some normal constituent of the body, 
(called a self antigen or autoantigen), or where there has 
been a combination of antibody and cell-mediated immune 
attack on some organ or cell system. Such diseases are 
termed "autoimmune diseases" (Smith and Steinberg, 1983;
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Shoenfeld and Schwartz, 1984). The term is normally used to 
describe disorders where the autoimmune response against an 
autoantigen contributes to the pathogenesis of the disease. 
It is also commonly used to describe diseases associated with 
the presence of autoantibodies, even when the pathogenic 
significance of these antibodies is not known.
There are a variety of autoimmune disorders. Some 
involve predominantly organ-specific autoimmunity, such as 
Hashimoto's thyroiditis, involving autoantibodies to 
thyroglobulin (Roitt et al, 1956; Kidd et al, 1980); 
thyrotoxicosis or Graves ' disease, involving antibodies to 
thyroid-stimulating hormone (TSH) receptors on the surface of 
thyroid cells (Doniach, 1975; McKenzie, 1976); myasthenia
gravis , involving autoantibodies to acetyl choline receptors 
in skeletal and heart muscle (Lindstrom, 1979).
Alternatively, the autoimmune phenomena may involve a 
broad spectrum of tissues. Systemic lupus erythematosus 
(SLE) is characterized by autoantibodies against a variety of 
cells, including erythrocytes, platelets and neurones and 
against a variety of antigens, including nucleic acids, blood 
clotting factors, and IgG. Nonspecific organ autoimmunity is 
also present in autoimmune po 1yendocrinopathy (Bottazzo et 
al, 1974; MacCuish et al, 1974; Neufeld et al, 1980),
characterized by autoantibodies to various endocrine tissues 
and antigens including adrenal cortex, thyroid microsomes,
thyroglobulin, gastric parietal cells and pancreatic islets.
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There has been increasing evidence that the pathogenesis 
of Type 1 (insulin-dependent) diabetes mellitus (IDDM) 
involves an autoimmune component. It was observed that some 
endocrine diseases attributed to immunological processes were 
associated with diabetes. Autoantibodies to a variety of 
tissues have been detected with higher frequencies in Type 1 
diabetic subjects, than in control subjects. There is an
association of Type 1 (insulin dependent) diabetes with 
certain HLA antigens. Histological insulitis' (lymphocytic
infiltration of the islets of Langerhans) have also been 
reported in a number of acute juvenile untreated diabetics 
(Gepts, 1965). There was already circumstancial evidence 
that Type 1 diabetes involved autoimmune factors in its 
aetiology, before the detection, in 1974, of autoantibodies
in the sera of diabetics that targeted pancreatic islet 
cells. The main lines of evidence that Type 1 (insulin 
dependent) diabetes may involve an autoimmune pathogenesis
are described in greater detail below.
1•1■2 Diabetes and Autoimmunity to Endocrine Tissues 
The first evidence that immunological factors were 
involved in the aetiology of diabetes, was the association 
between Type 1 (insulin-dependent) diabetes and other 
endocrine diseases that involve immunological processes. 
Examples of these diseases reported are Schmidt's syndrome, 
the combination of adrenalitis and thyroiditis (Solomon et 
al, 1965); Addison's disease (autoimmune adrenocortical 
atrophy) involving autoantibodies to cells of the adrenal 
cortex (Nerup, 1984); primary hypothyroidism involving
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autoantibodies to thyroid tissue antigens (Perlman, 1961; 
Ganz and Kozak, 1974); Hashimoto's thyroiditis, also 
involving autoantibodies to thyroid antigens (Landing et al, 
1963); hypoparathyroidism involving autoantibodies to 
parathyroid antigens (Blizzard, 1969); pernicious anaemia 
involving autoantibodies to intrinsic factor and gastric 
parietal cells (Ungar, 1968; Nerup and Binder, 1973; Irvine 
et al, 1970). Coexisting circulating autoantibodies to 
thyroid, gastric and adrenal tissues in sera of Type 1 
diabetics have been reported (Goldstein et al, 1970). It is 
now clear that in Type 1 diabetes, there is a greater 
frequency of autoimmune reactivity to other tissues, as well 
as to pancreas. The association with autoimmune diseases has 
a greater frequency in diabetic patients than in the normal 
population (Whittingham et al, 1971; Irvine, 1980; Nerup and 
Lernmark, 1981; Better le et al, 1984; Maclaren and Riley,
1985).
Despite the detection of autoimmunity to other tissues, 
autoantibodies to pancreatic islet cells were not detected 
until 1974. In that year, two groups published important 
findings (Bottazzo et al, 1974; MacCuish et al, 1974). These 
studies reinforced the previous evidence that Type 1 (insulin 
dependent) diabetes mellitus was a disorder that involved 
autoimmunity. However, it was not clear what role(s) these 
islet cell antibodies (ICA) played in the aetiology of the 
disorder. Studies with sera from Type 1 IDDM patients have 
revealed autoantibodies against a variety of tissues and 
antigens in addition to those already described. The list of 
other tissues and antigens targeted include TSH receptor
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(Bliddal et al, 1984); anterior pituitary cells (Mirakian et 
al, 1982; Sugiura et al, 1986); pancreatic A-cells (Bottazzo 
and Lendrum, 1976); adrenal medullary cells (Schopfer et al, 
1984), lymphocytes (Serjeantson et al, 1981), tubulin
(Rousset et al, 1984) and nuclear antigens (Huang et al,
1981; Bottazzo et al, 1983a).
A recent review has collated data from a number of
studies comparing the frequency of autoantibodies in patients 
with Type 1 diabetes mellitus and control subjects (Drell and 
Notkins, 1987). It was shown that more Type 1 diabetic 
patients than controls had autoantibodies to various tissue 
antigens, in addition to endocrine tissues. The authors 
pooled data from available reports and calculated the 
incidence of autoantibodies in Type 1 diabetic patients 
relative to control subjects. The relative incidences were 
expressed as percentages. Some data for the relative 
incidences of endocrine autoantibodies are as follows; 
thyroglobulin, 107. in diabetics compared with 4.47. in 
controls; thyroid microsomal antigens, 17.97. compared with 
5.8%; thyroid-stimulating autoantibodies, 32.67. compared with 
0%; gastric parietal cells, 11.17. compared with 5.8%; adrenal 
medulla 39.57. compared with 0.7%; adrenal cortex, 1.97. 
compared with 0.5%; and anterior pituitary, 19.7% compared 
with 0% (Drell and Notkins, 1987).
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1.1.3 Insulitis
In 1965, Gepts reported morphological studies of 
pancreases from Type 1 diabetic patients, showing major 
abnormalities in the number of B-cells , and the presence of 
inflammatory cells in the islets of Langerhans (Gepts, 1965). 
Subsequent studies after diagnosis of Type 1 IDDM confirmed 
the earlier results and have shown an invasion of lymphocytes 
within the islet cells that is primarily associated with 
B-cells and their specific destruction (Gepts and De Mey, 
1978; Foul is and Stewart,1984). The disappearance of B-cells 
is associated with a diminished mass of the endocrine 
pancreas, although the mass of A (glucagon), D (somatostatin) 
and PP (pancreatic polypeptide) cells appear to be normal 
(Rahier et al, 1983). The biobreeding (BB) rat is an animal 
model that spontaneously develops a diabetic syndrome with 
many similarities to human Type 1 (insulin dependent) 
diabetes (Marliss et al, 1982). It is believed that 
autoimmune responses play an importaant role in the 
pathogenesis in the rat model. Recently, studies have 
suggested that macrophages (Kiesel et al, 1986), and natural 
killer (NK) cells (McKay et al,1986; Woda and Biron, 1986)
may be involved in the B-cell damage in the diabetes-prone BB
rat. Evidence to support these findings have been the 
prevention of lymphocytic insulitis (and also lymphocytic 
thyroiditis) in BB rats treated with silica (Lee et al,
1988). Silica is selectively toxic to macrophages (O'Rourke
et al, 1978). Recently, a polyclonal antibody anti-asialo-GMl 
(AGMl) that binds to the glycolipid AGMl on NK cells (thus 
reducing their activity) was used to prevent recurrent 
autoimmune phenomena in BB rats (Jacobson et al, 1988).
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1 • 1 ■ 4 Genetic -factors and Type 1 IDDM
Studies o-f diabetic identical twins have shown that for 
Type 1 diabetes there is a 50% concordance (one twin has 
diabetes, the other has not), (Barnett et al, 1981).
However, for Type 2 diabetes about 90% of the pairs are
concordant for the disease. This suggests that for Type 2
diabetes, there is a strong inherited component, and genetic 
factors probably predominate in its aetiology. Although Type 
1 diabetes cannot be caused entirely by genetic factors, 
recent studies suggest that there is an important
immunogenetic component.
Evidence suggests that susceptibility to Type 1 diabetes 
is conferred by a gene or genes at a locus or loci, closely 
linked to the histocompatibility antigen (HLA) region. The 
major histocompatibility complex' (MHC) is the collection of 
genes that code for the major HLA. The HLA system is located 
on the short arm of chromosome 6 and is concerned with immune 
response. HLA-A, B and C loci code for class I antigens.
The HLA-D region codes for three sets of class II molecules:
DP, DO, and DR in man. HLA-A, B, and C molecules are found 
on all nucleated cells and platelets. HLA-D/DR molecules, 
however, are found on endothelial cells, Langerhans cells, 
macrophage, some epithelial cells, B-lymphocytes and 
activated T-lymphocytes. They are not expressed on normal 
pancreatic B-cells. Class II molecules are important in the
immune response. In order to respond to foreign antigens,
helper T-lymphocytes require antigen-presenting cells (ARC) 
such as macrophages, to present foreign antigens together 
with Class II molecules.
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There is evidence for a link of Type 1 IDDM to certain 
of the components of the major histocompatibility complex 
(MHC). The associations between Type 1 IDDM and HLA antigens 
have been reported since the mid-1970s (Nerup et al, 1974; 
Cudworth and Woodrow, 1975; Ludvigsson et al, 1977). 
Positive associations were described for HLA-B15, and BB. 
However, the strongest association is found to the HLA-DR3 
and/or HLA-DR4 tissue types (Platz et al, 1981; Cudworth and 
Wolf, 1982; Wolf et al, 1983). Wolf and coworkers have 
reported a relative risk of development of Type 1 diabetes of 
5.0 and 6.8 for DR3 and DR4 respectively. The approximate 
additive relative risk is 14.3 for the presence of both DR3 
and DR4 (Wolf et al, 1983).
The DR3 and/or DR4 types occur with a high frequency, 
about 507. in the non-diabetic population, and although Type 1 
diabetes mainly affects the DR3 and DR4 population, its 
prevalence is 0.37.. This has led to the suggestion that the 
DR molecules are not directly involved in the pathogenesis of 
the disease. Instead, some subset of DR3 or DR4 or a closely 
linked (but distinct) locus, contains the diabetogenic' or 
disease susceptibility' gene(s), (McDevitt and Bodmer, 
1972). These genes are thought to be in 'linkage
disequilibrium' with the HLA-DR genes. Linkage
disequilibrium arises within populations when particular 
alleles at closely linked loci occur together on the same 
chromosome more often than would be expected by chance. This 
phenomenon is well established for HLA system antigens 
(Bodmer and Bodmer,1978), thus suggesting the possible 
existence of a diabetogenic gene.
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Recent molecular cloning of the HLA-D region genes, have 
revealed that each locus of the HLA-D region codes for one or 
several alpha or beta chains (Shackelford et al, 1982; Bodmer 
and Bodmer, 1984). A cloned probe for one of the HLA-DO 
B-chain genes (Wiman et al, 1982) was used in DNA-DNA 
hybridization analyses, referred to as restriction fragment 
length polymorphism (RFLP) analyses. These studies were 
applied to HLA-DR identical control and diabetic individuals 
(Owerbach et al, 1983), and to linkage analysis in HLA-DR 
typed control and diabetic families (Owerbach et al, 1984). 
These studies showed that the po 1ymorphism detec ted by the
HLA-DO B chain was associated with HLA-DR. Also, HLA-DR
identical control and Type 1 diabetic patients differed in 
the presence of certain restriction fragments. These studies
suggested that DNA probes, rather than tissue-type alone,
might better define the risk of developing diabetes.
1•1•5 Islet Cell Antibodies
Despite some evidence of an association between diabetes 
and autoimmunity, humoral islet cell antibodies (ICA) had not 
been detected in sera of diabetics until investigations by 
Bottazzo and coworkers (1974), and also MacCuish and 
coworkers (1974). Islet cell antibodies were detected in 
patients with diabetes and po1yendocrine diseases, and it was 
postulated that they were directly involved in the 
pathogenesis of Type 1 diabetes mellitus. Subsequent 
investigations have detected circulating ICA in over 607. and 
up to 907. of newly diagnosed insulin-dependent diabetic 
patients (Lendrum et al,1976; Del Prete et al, 1977; Lernmark
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and Baekkeskov, 1981; Herold et al, 1984; Dobersen, 1985). 
Their presence has also been detected in patients with other 
autoimmune endocrinopathies (Irvine, 1979b; Bottazzo et al, 
1984).
The early studies of islet cell antibodies were
performed using immunofluorescence staining of pancreatic 
tissue sections. The technique most easily detected
autoantibody reactivities to cytoplasmic antigens of islet 
cells. The use of complement factor C3 and fluorescent
antibodies to C 3 , enabled the detection of complement-fixing 
autoantibodies to islet cells. Assay techniques were
subsequently developed for the detection of islet cell
surface antibodies. It was then possible to differentiate
between apparently different types of islet cell antibodies,
although the nature of the autoantigens being targeted were 
unknown. Currently, islet cell antibodies are classified
into two main subtypes:
a ) Islet Cell Cytoplasmic Autoantibodies
Antibodies present in sera of IDDM patients were first 
detected by indirect immunofluorescence staining on unfixed 
cryostat sections of human blood group O pancreas (using
anti-human IgG fluorescein-isothiocyanate conjugates to
detect bound immunoglobulins), (Bottazzo et al, 1974;
MacCuish et al, 1974; Lendrum et al, 1975,1976). Pancreases 
from blood group 0 donors were used to prevent interference 
from isoagglutinins. This method detects . antibodies to the 
cytoplasm of islet cells, referred to as islet cell
cytoplasmic antibodies (ICCA). ICCA are primarily of the IgG
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class and react with cytoplasmic components of all the 
endocrine cell types in the islets (insulin, glucagon, 
somatostatin, and human pancreatic polypeptide cells). The 
antigen(s) detected by ICCA are not clearly understood. 
There has been much debate as to whether ICCA have a primary 
role in the pathogenesis of Type 1 diabetes, or whether they 
are a secondary immunological phenomenon. It has been
suggested that ICCA occur through an immune response to 
intracellular components that are exposed from 0-cells
damaged by some primary cytolytic mechanism. ICCA would thus 
be an indicator of previous or ongoing 0-cell destruction. 
Evidence that these antibodies are a marker of the
development of Type 1 diabetes, is the detection of ICCA in 
serum years before the clinical onset of IDDM (Gorsuch et al, 
1981; Ginsberg-Fe11ner et al,1985). This has been correlated 
with a progressive decrease of 0-cell function, determined by 
the intravenous glucose tolerence test (IVGTT) (Srikanta et 
al, 1983; 1985).
Complement-fixing islet cell antibodies (CF-ICA) have 
also been detected (Bottazzo et al, 1980). These antibodies
are usually of the IgG class and are present in most
diabetics who are ICCA positve. They are often present in 
lower titer than ICCA and have also been shown to correlate 
with the onset of IDDM. The appearance of these
autoantibodies imply a role in pancreatic 0-cell damage, in 
that they may be cytotoxic. CF-ICA may also be of value as a 
marker of the pre-diabetic phase as these antibodies have 
been shown to appear years before the clinical manifestation 
of the disease (Gorsuch et al, 1981; Mustonen et al, 1984).
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b ) Islet Cell Surface Autoantibodies
Lernmark and coworkers (1978) used an indirect 
immunofluorescence assay to detect the presence of antibodies 
directed against the cell surface of islet cells. Their 
assay method involved indirect immunofluorescence staining of 
cell membranes of viable insulin-secreting cells prepared 
from isolated mouse or rat islets. Islet cell surface 
antibodies (ICSA) were thought to be directed against 
insulin-cell plasma membane antigenic determinants. A high 
prevalence of ICSA (607.) was found in a study of diabetics 
prior to insulin therapy (Lernmark et al, 1981). Here, it 
was found that the incidence of ICSA decreased with 
increasing duration of the diabetes.
ICSA have been shown to be organ-specific rather than 
species-specific (Lernmark et al, 1978). They have also been 
shown to be 8-cell specific (Van de Winkel et al, 1982). 
Some studies investigated the effects of ICSA on B-cell 
function (Lernmark et al, 1979; Kanatsuna et al, 1981, 1982,
1983). Kanatsuna and coworkers (1983) used immunoglobulin 
prepared from sera of newly diagnosed Type 1 diabetic 
children and co1umn-perifused dispersed rat islet cells. 
They found that the immunoglobulin fraction from 
ICSA-positive Type 1 diabetic patients inhibited 
glucose-stimulated insulin release. It was suggested that 
the inhibitory effect might be due to antibody binding to 
cell surface determinants or to a hypothetical membrane 
receptor. Thus, inhibitory antibodies might suppress B-cell 
function and so contribute to the pathogenisis of the 
disease. More recent studies (Alden et al, 1984) have also
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suggested that ICSA in sera from Type 1 diabetic children 
might interfere with B-cell function in vitro.
ICSA are able to mediate complement-dependent cellular 
cytotoxic reactions against various islet cell targets: rat
islets (Dobersen et al, 1980), hamster islets (Rittenhouse et 
al, 1980), and rat insulinoma cells (Toguchi et al, 1985). 
In these studies, ICSA were detected in 40-607. of Type 1 
diabetic patients, and the cytotoxic reaction has also been 
shown to be B-cell specific (Dobersen and Scharff, 1982). It 
has thus been suggested that islet cell surface antibodies 
(ICSA) may represent a primary pathogenic mechanism against 
the pancreatic B-cells. It is possible that cytotoxic ICSA 
exist in the sera of individuals during the period of 
progressive B-cell destruction which can precede the clinical 
symptoms of diabetes. Islet intracellular antigens that 
become exposed to the immune system would thus elicit the 
production of ICCA (autoantibodies to cytoplasmic
components).
Duration of Islet Cell Autoantibodies
In the majority of endocrine autoimmune disorders, 
antibody production continues for many years, even when the 
target organ is atrophied (Shoenfeld and Schwartz, 1984). 
Examples of these are the organ-specific antibodies such as 
gastric parietal cell, thyroid and adrenocortical antibodies 
that characterize pernicious anaemia, primary atrophic 
hypothyroidism and idiopathic Addison's disease respectively 
(Irvine, 1979a; Volpe, 1985). Islet cell antibodies (ICSA
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and ICCA) are found to decline after diagnosis of Type 1
diabetes, and may persist in only 10-207, of cases after 2 
years (Irvine et al, 1977; Kolb et al, 1980; Bottazzo et al, 
1981). The reasons for this are unclear. It has been 
suggested that islet cell antibodies decline due to the
disappearance of autoantigen(s) due to the progressive 
destruction of islet cells. Other autoantibodies that are 
associated with Type 1 diabetes are also found to decline 
with time (Drell and Notkins, 1987). In their recent review, 
Drell and Notkins summarized the evidence that insulin had a 
corrective effect on some immunological abnormalities in 
drug-induced animal models of diabetes. They suggested that
the decline of autoimmune phenomena observed in patients
after diagnosis of Type 1 diabetes might be partly due to
insulin therapy.
Predictive significance of Islet Cell Antibodies 
There have been various studies that have demonstrated
that islet cell antibodies may be useful in the prediction of
Type 1 diabetes in individuals that have an increased risk of
developing the disease, (first degree relatives of Type 1
diabetics, are examples of such individuals), (Gorsuch et al, 
1981). In a five year follow-up study of 16 ICA-positive 
non-diabetics, 3 developed diabetes and CF-ICA was found to 
be a good predictive factor (Better le et al, 1982). Gorsuch 
and coworkers (1982) found that the probability of developing 
diabetes in a healthy parent or sibling who is CF-ICA 
positive is 737.. Despite several cross-sectional clinical 
studies of islet cell antibodies, it remains unclear whether
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they are causal or a consequence of cell damage. The 
pathogenic mechanism of these antibodies and the antigenic 
determinants that they target are still poorly understood. 
However, there is strong evidence that these autoantibodies
are markers of (3-cell destruction, and sensitive and 
reproducible assays for ICA would contribute to studies in 
the prediabetic' phase.
Islet Cell Autoantigens
The precise nature of the islet cell antigens that are 
targeted by islet cell antibodies is unclear. The fact that 
there are subclasses of islet cell autoantibodies whose 
presence in IDDM sera do not necessarily coincide, suggest 
that there might be different antigens involved. These 
antigens are thought to be cell membrane bound, and 
intracellular. Lernmark and coworkers have reported the use 
of sera from newly diagnosed Type 1 diabetics to
immunoprecipitate proteins from human islet cells (Baekkeskov 
et al, 1982). They identified a 64K dal ton protein. In 
subsequent studies, the protein was reported to be
amphiphilic, and therefore possibly a membrane-bound protein 
(Baekkeskov et al, 1985). These studies have suggested that 
this protein might represent an islet cell surface 
autoantigen that is targeted by the ICSA. More recently, 
some preliminary studies were made of the appearance of 
antibodies to the Mr 64000 protein, in sera of patients
followed before the clinical onset of IDDM (Baekkeskov et al,
1986). The function of this protein is not yet known.
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There is a recent report that pancreatic glycolipid 
extracts are able to block cytoplasmic ICA binding to frozen 
sections of human pancreas (Colman et al, 1988). It has thus 
been suggested that the cytoplasmic autoantigen(s), targeted 
by ICCA, are glycolipid in nature. It is possible that 
antibodies to these glycolipid antigens appear as a secondary 
phenomenon, after islet cell damage. More detailed studies 
are needed to characterize these different antigens and to 
establish their roles in the autoimmune processes of Type 1 
d i abetes.
1.1.6 Possible Mechanisms of Autoimmune (3-cell 
destruction
The diversity of immunological abnormalities, and 
immunogenetic associations present in Type 1 (insulin
dependent) diabetes, suggest that its aetiology is 
multi factorial. The exact pathogenic mechanisms and their 
precise combination, are not clear. However, it is possible 
to suggest a plausible sequence of events that could lead to 
the onset of the disease.
Viral infection is associated with Type 1 diabetes (Yoon 
et al.,1979). Consequently, there has been much interest in 
the possible existence of diabetogenic organisms such as
viruses or bacteria. It is possible that chemicals, 
infectious viruses or bacteria could modify an islet cell 
antigen, thus resulting in altered self. Chemicals could 
cause tissue damage, and thus initiate an immune response. 
It is also possible that an infectious agent possesses
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antigenic epitopes that cross-react with a 3-cell surface 
antigen. Such an organism could initiate a sensitization of 
T-helper cells that activate B-lymphocytes and the secretion 
of antibodies that recognise the 3-cell autoantigen. These 
antibodies could be the ICSA. The viral infection would 
cause an increase in interferon levels and an increased 
expression of MHC class II histocompatibility antigens on 
cells of the immune system and on vascular epithelium. It is 
thought that quantitative increases in class II expression 
may play an important role in the induction of 
immunologically mediated disease (Janeway et al, 1984). It 
is also thought that certain class II antigens may be able to 
associate with a given antigen in a way that initiates the 
highest response from T-helper cells (Babbitt et al, 1985). 
It has been suggested that endocrine autoimmunity may be 
initiated by aberrant expression of MHC class II antigens on 
endocrine cells (Bottazzo et al, 1983b). These endocrine 
cells are thought to act as antigen-presenting cells for 
their own surface antigens.
Damage to the pancreatic 3-cells could occur by ICSA 
interacting with complement (Rittenhouse et al, 1980; Toguchi 
et al,1985) or killer cells, or by the action of cytotoxic 
T-cells. 3-cell specific cell surface antigens could then be 
presented with class II antigens on incoming macrophages. 
Cross-reacting T-helper cells could target the pancreas, thus 
resulting in an enhanced response to the autoantigen. There 
could be an increase in levels of circulating ICSA and an 
increase in infiltrating lymphocytes forming an insulitis in 
the pancreatic islets. Since 3-cells are able to express
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class II antigens, there may be a recurring cytolytic immune 
response to the 3-cells and the release of cytoplasmic 
components.
A secondary immune response to the islet cell 
cytoplasmic components might then occur, resulting in the
appearance of circulating ICCA. It is possible that 3-cell 
death reaches a critical limit as a result of subsequent 
environmental insults (chemical or viral), or after a chronic 
destruction process. When the remaining functional 3-cells 
are unable to meet the body's insulin requirements, clinical 
symptoms of IDDM result.
Since there may be a genetic component involved in the 
aetiology of the disease, it is possible that 3-cell damage 
is elicited by some trigger such as a viral infection, and 
that the development of IDDM occurs in genetically 
susceptible individuals. The nature of the initial factor 
that precipitates the pathogenic mechanisms in the disease, 
is still unclear.
Immunoregu1at i on
It is possible that the autoantibodies to a wide variety
of antigens, that appear in association with diseases such as 
SLE and rheumatoid arthritis, arise partly as a result of 
some perturbation in the regulation of the immune system. It 
is possible that some of the non-specific autoimmunity in 
Type 1 diabetes may be due to some regulatory dysfunction. 
The immune system has a latent ability to produce
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autoantibodies. There is evidence that potentially
autoreactive B- and T-lymphocytes exist in normal 
individuals. For example, a small number of B-lymphocytes 
can bind radioactive human thyroglobulin (Bankhurst et al, 
1973). Also B-lymphocytes in a wide variety of vertebrates 
can be induced to produce autoantibodies by immunization with 
thyroglobulin (ElRehewy etal, 1981). Evidence also exists 
that autoreactive T-lymphocytes can play a role in
autoallergic thyroiditis induced in good responder' mice 
(Vladutiu and Rose, 1975). The expression of spontaneous 
thyroid autoimmunity in obese strain chickens requires the 
presence of T-helper lymphocytes (de Carvalho et al, 1981). 
It is conceivable that autoimmunity could arise through some 
perturbation of the regulation of the immune network, 
resulting in the loss of controlling mechanisms that normally 
restrain autoreactive cells. This control may be thought of 
in terms of a suppressor T-cell system (Allison et al, 1971),
in which some degree of dysfunction would lead to the
development of autommunity. In Type 1 diabetes mellitus, it 
is not clear why there is an increased prevalence of 
autoantibodies to a variety of tissues and antigens, as well 
as specific islet cell autoantibodies (Drell and Notkins,
1987). Disturbances in immunoregu1 ation may account for some 
of these non-specific phenomena.
1.1.7 Significance of Multiple Tissue Autoimmunity 
Disorders involving autoantibodies to various tissues 
raised questions about the nature of the multiple tissue 
reactivity. Assuming that the autoimmunity was in response
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to the appearance of specific autoantigens, two possible 
explanations for this phenomenon have been suggested :
1) There are commonly shared' autoantigens that appear 
in different tissues. Autoantibodies that react with these 
autoantigens thus exhibit multiple-tissue reactivity.
2) The autoimmune sera contain a mixture of different 
tissue- or organ-specific autoantibodies. The mixture may be 
complex and contain specific autoantibodies to a wide variety 
of tissues. The sera would thus exhibit multiple-tissue 
reactivity.
The question of whether cross-reactive or
organ-specific' autoantibodies exist, and their relative 
proportions, has been the subject of some interesting studies 
(Satoh et al, 1983; Garzelli et al,1986). The possible 
existence of complex mixtures of autoantibodies and the 
possibility of their low titers have hindered studies of 
their immunochemical and functional properties. The precise 
pathogenic roles of these autoantibodies are thus unclear. 
One strategy towards elucidating the common-reactive' or 
organ-specific nature of the autoantibodies has been the 
use of hybridoma techniques. The immortalization and cloning 
of autoreactive B-lymphocytes provides a means of dissecting 
the immune response into its constituent specificities. Some 
work of this type has been reported through the production 
of human monoclonal autoantibodies that react with multiple 
endocrine organs (Satoh et al, 1983; Garzelli et al, 1986). 
Satoh and coworkers produced human monoclonal antibodies from
page
patients with p o 1yendocrine disorders and seven out of nine 
monoclonal autoantibodies obtained, reacted with antigens in 
a variety of endocrine organs. The authors suggested that 
the existence of multiple-organ-reactive antibodies and their 
relevant common autoantigenic determinants were a partial 
explanation for multiple organ autoimmunity in po 1yendocrine 
d i sease.
1.2 MONOCLONAL ANTIBODIES AND THE STUDY OF AUTOIMMUNITY
The immune system has been a supplier of reagents for a 
wide number of applications in biology and medicine, due to 
its ability to produce antibodies with precise specificities 
to defined antigens. Due to its polyclonal nature, the 
specificity of an antiserum is affected by the presence of 
even small amounts of impurities in the immunogen, which 
elicit unwanted antibodies. Before the advent of monoclonal 
antibody production by somatic cell hybridization, the 
preparation of monospecific antibodies of high titer usually 
required the purification of antigen, and careful 
immunization of animals, with repeated boosting and 
bleeding. The technique for making monoclonal antibodies 
through the immortalization of individual antibody-secreting 
cells, provided a means of overcoming the problem of unwanted 
antibodies (Kohler and Milstein, 1975). Kohler and Milstein 
developed the technique over a decade ago when they induced 
the somatic cell hybridization between cells of a murine 
myeloma and splenocytes derived from a mouse immunized with 
sheep red blood cells (SRBC). Hybridomas were selected for
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and found to secrete anti-SRBC antibodies. The continuous
culture of hybridoma cells, provided they were stable, also 
made possible the generation of unlimited quantities of
monospecific antibodies.
It is now possible to use impure antigens in the 
immunization of animals, and the production of lymphocyte
hybridomas that secrete specific monoclonal antibodies. This 
is true, provided one has a reliable screening system for the 
specific antibodies desired. The murine system has been the 
most utilized in the production of monoclonal antibodies. 
Monoclonal antibodies from murine hybridomas have been used
for a wide variety of applications. Hybridoma reagents have 
helped to elucidate the structures and functions of cell 
membrane components, enzymes and many other proteins. As 
diagnostic tools, monoclonal antibodies are used routinely as 
reagents in immunoassays for the quantification of serum 
immunoglobulins and proteins. The technique has also been 
used to produce antibodies that are tools for the analysis of 
complex biological systems.
An example of the analysis of complex biological
processes, is the recent use of hybridoma techniques in the 
study of autoimmune diseases. Mouse and rat monoclonal 
antibodies have been utilised in studies of autoimmunity. 
Studies in human autoimmunity, have not been extensive, due 
to some technical difficulties in producing stable hybridomas 
that secrete human monoclonal antibodies. There is great 
interest in the routine production of human monoclonal
antibodies, and there would be important potential
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applications of such reagents.
Hybridoma techniques have been employed in the study of 
autoimmune disorders involving organ-specific autoantibodies 
(Type 1 diabetes, thyroid disorders), as well as those 
involving autoantibodies to a variety of antigens in 
different tissues (SLE, Po 1yendocrine Autoimmunity).
1.2.1 Monoclonal Antibodies and SLE
Studies in systemic lupus erythematosus (SLE) have used 
strains of spontaneously lupus-prone mice whose immune cells 
have been hybridized with plasmacytoma cells (Bussard and 
Pages, 1978). The New Zealand Black (NZB) mice is a strain 
that spontaneously develops SLE, and the first hybridomas 
obtained secreted anti-erythrocyte antibodies of class IgM. 
The majority of monoclonal antibodies produced in subsequent 
studies have reacted with nucleic antigens, especially RNA 
and DNA (Eilat , 1982).
Recently, human hybridomas from patients with different 
autoimmune diseases have been constructed in attempts to 
study the pathogenic autoantibodies. One study involved five 
patients with different autoimmune phenomena, including cold 
agglutinin disease, atopic allergy, and systemic lupus 
erythematosus. Peripheral blood lymphocytes were fused with 
human myeloma fusion partners and resultant hybridoma 
supernatants had activity against single-stranded DNA, 
platelets and erythrocytes (Shoenfeld et al, 1982). Other 
studies (Shoenfeld et al, 1983; Littman et al, 1983) have 
demonstrated the polyspecificity of monoclonal anti-DNA
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autoantibodies. These autoantibodies also react with other 
polynucleotides and also with phospholipids (Shoenfeld et al, 
1983; Lafer et al, 1981). Although the clinical significance 
of such autoantibodies is not clear, the technique has 
provided an important tool for exploring the complex 
immnological phenomena involved in the disease.
1.2.2 Rodent Monoclonal Antibodies and ICA
The hybridoma technique has been applied to research in 
the autoimmunity of diabetes. Rodent monoclonal antibodies 
that react with islet cells have been produced by Eisenbarth 
and coworkers. They were obtained by the following methods.
1) Immunization of mice with rat islet cells and rat 
islet tumour cell line RINmSF (Eisenbarth et al, 1981b; Crump 
et al, 1982). One antibody AID2, produced by immunization 
with RINm5F cells, was specifically cytotoxic to rat islet 
cells in vitro. It was found to bind to a small 24K 
glycoprotein on the cell surface of islet cells.
2) Production of rat monoclonal autoantibodies produced
by fusing spleen cells from a diabetic prone BB rat with the
P3X63 murine myeloma cell line (Buse et al, 1983). Antibody 
A1G12 displayed preferential binding to rat pancreatic islet 
cells, but also showed an anti-nuclear' rim flourescence and 
binding to a cytoplasmic component of rat islet cells.
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Over the last decade, there has been a surge of interest
in the immunological processes of Type 1 diabetes, marked by
the increasing number of studies on the subject. This has
been a testimony to the complexity of the various
immunological abnormalities associated with the disorder.
The studies in the following chapters describe the use of the
hybridoma technique to probe some of the autoimmune phenomena 
present in Type 1 (Insulin dependent) diabetes mellitus, and
the development of routine assays for the detection of islet
cell surface antibodies. ,
page 27
CHAPTER TWO
PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES 
FROM A DIABETIC PATIENT
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CHAPTER 2 : PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES
FROM A DIABETIC PATIENT
2.1 INTRODUCTION
The development of hybridoma techniques to produce 
monoclonal antibodies from specific antibody-secreting cells 
has been an important contribution to immunological research 
(Kohler and Milstein, 1975). The technique makes possible 
the immortalization' of cells secreting specific antibody, 
despite their relatively low frequency and polyclonality in 
peripheral blood, as is the case in autoimmune disorders. 
The technique has obvious applications in the analysis of 
these disorders. The following study describes the use of 
human heterohybridoma techniques to probe multiple endocrine 
autoimmune phenomena present in Type 1 insulin-dependent 
diabetes mellitus.
2.1.1 Applications of Human Monoclonal Antibodies
There is great interest in the reliable production of
human monoclonal antibodies and their subsequent use as 
immunodiagnostic and immunotherapeutic tools (Kozbor and 
Roder, 1983; Boyd et al, 1984; James and Bell, 1987). The 
murine immunoglobulin reagents that are available for 
therapeutic purposes are unsuitable primarily because the 
development of an immune response by the host against murine 
proteins might neutralize their therapeutic effects, and 
trigger dangerous allergic reactions. In contrast, one would 
expect human immunoglobulins to persist in the circulation 
for longer, and that they would be less likely to elicit 
vigorous antibody responses recipients.
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Examples of potential uses could include:
1) Diagnostic imaging to identify malignant cells, such 
as myeloid leukaemia (Andreasen and Olsson, 1986).
2) Passive immunization to neutralize viruses such as 
cytomegalovirus (Emanuel et al, 1984) and hepatitis B (Van 
Meel et al,1985), and bacteria such as Pseudomonas aeruginosa 
(Sawada et al, 1985) and haemophilus influenzae (Hunter et 
al, 1982).
3) Active immunization with anti-idiotypic antibodies to 
elicit antibodies against pathogens for which no suitable 
conventional vaccines yet exist.
4) Modulation of autoimmune and endocrine conditions 
that involve autoantibodies, through the use of 
anti-idiotypic antibodies. The anti-idiotypic antibodies may 
be useful in the in vitro detection and quantification of 
pathogenic autoantibodies, as well as therapy through 
immuno-neutralization of these autoantibodies in vivo 
(Chiorazzi, 1986).
The possibility of successfully immortalizing human 
immunoglobulin secreting cells also has important 
applications in the study of autoimmune disorders, where the 
immune response usually involves complex mixtures of 
autoantibodies. If successful, these potential applications 
would have a major impact on medical research, and so methods 
for the routine production of human monoclonal antibodies 
have been pursued by many laboratories. However, there have 
been some technical difficulties which have hindered 
progress.
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2.1.2 Production of Human Monoclonal Antibodies
The most common techniques available for the production 
of human monoclonal antibodies involve different ways of 
immortalizing lymphocytes that secrete antibodies. The two 
most used techniques are: a )Epstein-Barr virus transformation
and b) Cell fusion.
EBV-Transformation of B Lymphocytes
Epstein-Barr virus (EBV) is a herpes virus that infects 
primate B-lymphocytes and causes infectious mononucleosis 
(glandular fever). It was demonstrated that culture 
supernatants containing EBV could induce cell division and 
transformation of human B lymphocytes (Rosen et al, 1977), 
and that infected cells grow indefinitely in medium lacking 
exogenous growth factors.
Some years before the application of hybridoma 
technology to the production of human monoclonal antibodies, 
human lymphoid cell lines producing antibody of defined 
specificity were established by EBV-transformation and 
immortalization (Steinitz et al,1977). Direct super infection 
of purified human lymphocytes with EBV in vitro was shown to 
induce a polyclonal secretion of immunoglobulin. As a 
technique to immortalize human antibody-secreting cells, 
EBV-transformation is simple. However, it does have some 
limitations (Kozbor and Roder,1983; Carson and Freimark,
1986). Some of the shortcomings of the technique are as 
foilows:
1) It is necessary to clone EBV-infected B-lymphocytes 
early, in order to maintain specific antibody production.
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This is due to the polyclonal nature of the antibody 
secretion after transformation.
2) Transformed cells tend to grow inefficiently at low 
cell densities despite the addition of feeder layers and 
growth factors. This hinders the efficiency of cell cloning.
3) The transformed cell lines are relatively unstable in 
that they lose their secretion of immunoglobulin after about 
six months. To overcome this problem a combination of 
deriving EBV-infected 1ymphob 1 astoid cell lines, followed by 
immortalization using the cell fusion technique has been used 
with some results (Kozbor and Roder,1983; Carson and 
Freimark, 1986). This problem makes the technique somewhat 
tedious, with the added danger of losing secreting cell lines 
upon cloning.
Despite these problems, EBV transformation has been used 
in many laboratories to produce permanent cell lines 
secreting human monoclonal antibodies against viruses eg. 
Hepatitis B (Furuya et al,1982), influenza virus (Crawford et 
al,1983); bacteria eg. streptococci (Steinitz et al,1979), as 
well as other molecular antigens eg. rhesus D antigen 
(Boylston et al,1980).
Ce 11 Fus i on
The most popular method for the immortalization of 
immune lymphocytes is cell fusion with a continuous cell 
line, termed a fusion "partner", usually a myeloma (Boding, 
1982, 1986). This confers the "immortality" of the cell line
to the lymphocyte, which would otherwise die after prolonged
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culture. Although Kohler and Milstein initially used Sendai 
virus to elicit the fusion of murine lymphocytes with myeloma 
cells (Kohler and Milstein, 1975), the most frequently used 
"fusogen" now is polyethylene glycol, PEG (Pontecorvo ,1976). 
This is because of the difficulty of removing Sendai virus 
from the cell culture, as well as the relative ease of 
handling PEG. The most commonly used fusion partner cell 
lines are hypoxanthine guanine phosphoribonucleotidase 
(HGPRTase) negative. The lack of this "salvage pathway" 
enzyme means that in the presence of hypoxanthine, 
aminopterin and thymidine (HAT), aminopterin will be toxic 
since these cells are unable to utilize the nucleotides 
(Littlefield, 1964). Thus after fusion of lymohocytes with 
HAT-sensitive myeloma cells, only those cells that are 
hybrids of the two cell types may be selectively cultured by 
growth in the presence of HAT.
The first report of human monoclonal antibodies was in 
1980, by Olsson and Kaplan who produced human hybridomas 
secreting monoclonal antibodies against the 2,4-dinitropheny1 
hapten. The fusion partner used, was a human myeloma (Olsson 
and Kaplan, 1980). Since then many other fusion partners 
have been used. Most of the human fusion partners are 
lymphoblastoid cell lines. These are derived through 
trasformation of lymphocytes by Epstein-Barr virus. Other 
human fusion partners that have been used are human myelomas. 
However, these are considered to be less useful because of 
difficulties in maintaining continuous cell lines in culture 
(Kozbor and Roder, 1983). Unlike murine hybridoma
technology, there have not been any predominantly used human
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-fusion partners for human monoclonal antibodies (Samoilovich 
et al, 1987). Instead, many laboratories have developed
their own fusion partners. Some groups have constructed 
hybrids between lymphoblastoid lines and human or mouse
myelomas to use these as fusion partners (Teng et al, 1983). 
Many workers have also fused human lymphocytes with mouse 
myelomas (Hirohashi et al, 1986; Thompson et al, 1986) and 
successfully obtained human monoclonal antibody secretion.
Some technical difficulties have been encountered in the 
production of human monoclonal antibodies (James and Bell,
1987). The choice of lymphoid tissue for fusion is usually 
limited to peripheral blood lymphocytes (PEL). In PBL, there 
are less antigen specific cells in an ideal state of
differentiation for fusion than in other lymphoid tissues 
such as lymph node, tonsil or spleen (Schwaber et al, 1984). 
The efficiency of fusion with human fusion partners may be 
low compared to the mouse system, and when heterohybrids are 
formed they have a tendency to preferentially reject, as well 
as retain, certain human chromosomes. Human chromosomes 14 
(heavy chain) and 22 (light chain-K) are preferentially 
retained, wheras chromosome 2 (light chain-k) is 
preferentially lost (Croce et al, 1980; Erikson et al, 1981). 
This loss of human chromosomes may determine the frequency 
with which stable heterohybridomas are formed, and may thus 
affect the long-term secretion of human monoclonal 
antibodies.
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2.1.3 Human Monoclonal Antibodies and the 
Study of Autoimmunity 
In the study of autoimmune phenomena, it is necessary to 
determine the way in which the human immune system is 
involved in the disease process. Analyses of these processes 
have often been hindered by the complex network of the immune 
system itself. However, were it possible to dissect out the 
function of antibodies produced by different lymphocytes, a 
better understanding would be obtained of the nature and 
role(s) of the humoral immune response in the pathology of 
the disorder. Subsequently, it would be possible to discover 
and characterize the antigens responsible for eliciting these 
immune responses. The production of hybridomas secreting 
human monoclonal autoantibodies provides a powerful tool to 
dissect and study human autoimmune diseases that involve 
complex mixtures of autoantibodies. Important examples of 
such disorders in which hybridoma techniques have already 
been used as research tools are : Systemic Lupus
Erythematosus (Shoenfeld et al, 1982) and Po 1yendocrine 
Autoimmunity,(Satoh et al,1983). The use of hybridoma 
technology to produce human monoclonal antibodies is 
currently being pursued by many laboratories, because of the 
usefulness and potentially large quantities of such reagents. 
A homogeneous population of autoantibodies would, in 
principle, assist the study of their properties and help to 
elucidate unknown or poorly understood autoantigens.
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2.1.4 Human Monoclonal Islet Cell Antibodies
A number of problems accompany the study of islet cell
autoantibodies (ICA) that may appear in sera from patients
with Type 1 diabetes.
a) The low quantities of ICA in sera of Type 1 diabetics
and the polyclonal nature of sera, limit its use in the
determination of the precise specificities of ICA.
Furthermore, the detection of ICA is determined by the 
sensitivity of the assay methods used.
b) ICA may occur in complex mixtures with other
autoantibodies. This may lead to ambiguous immunochemical 
staining patterns, involving multiple tissue reactivities.
c ) Isolation and purification of the autoantibodies is 
difficult because the islet cell autoantigen(s) are poorly 
understood. Knowledge about the nature of the autoantigen(s) 
targeted by ICA would enable the development of more precise 
and sensitive ICA assays, as well as providing steps towards 
methods of purifying the ICA.
Human hybridomas have previously been produced from 
lymphocytes of patients with Type 1 diabetes. These were
found to have reactivity with pancreatic islet cells
(Eisenbarth et al, 1982). Circulating lymphocytes from a 
diabetic child were fused with human myeloma cells, GM 1500 
6GT-2. The first human monoclonal autoantibody produced, 
antibody B6, demonstrated indirect immunofluorescence 
staining of A-cells on frozen sections of human Type 0
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pancreas. B6 was an IgM monoclonal antibody lacking the 
parental IgG chain of the GM 1500 cell line. The reactivity 
of antibody B6 was not neutralized upon absorption with the 
hormone glucagon, indicating that the target was not the 
hormone, but some other unknown molecule.
2.1.5 Autoantibodies in Graves' disease
Graves' disease (thyrotoxicosis) is an organ-specific 
autoimmune disorder of the thyroid, involving autoantibodies 
to the thyroid stimulating hormone (TSH) receptor (Adams, 
1980). These autoantibodies are thought to have a direct 
role in the hyperthyroid state of these patients. Generally, 
there are two main types of antibodies that bind to the TSH 
receptor on thyroid follicular cells. They are classified 
into those that have a stimulatory role (they mimic TSH), and 
those that bind to the TSH receptor in a manner that inhibits 
thyroid function. These thyroid-blocking autoantibodies also 
occur in myxoedema (Drexhage et al, 1981). Further studies 
on anti-TSH receptor autoantibodies from Graves patients 
demonstrated their ability to inhibit TSH binding as well as 
to stimulate adenylate cyclase activity in cultured thyroid 
cells. This suggested that a spectrum of different 
autoantibodies might exist and the use of hybridoma 
techniques could help to dissect the mixture of antibodies.
Valente and coworkers produced four human monoclonal 
antibodies against TSH receptors, obtained by fusing 
peripheral lymphocytes from patients with Graves' disease 
with mouse myeloma cells (Valente et al, 1982). All four of 
the antibodies specifically inhibited TSH binding to cultured 
thyroid cells. Two of these stimulated thyroid function in
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several assay systems and also were reactive with the 
ganglioside component of the TSH receptor. These were
thought to represent the stimulatory antibodies in Graves 
disease. By contrast, the other two antibodies inhibited the 
action of TSH in the assay systems, and reacted with the high 
affinity glycoprotein component of the receptor. These were 
thought to be representative of the "blocking" antibodies in
Graves sera. The reasons for the occurence of anti-receptor
antibodies in Graves' disease are unclear. It has been 
suggested that receptor-specific autoantibodies may arise 
through the triggering of an idiotype/anti- idiotype cascade. 
Anti-receptor antibodies may in fact be anti-idiotypic
antibodies. It has been demonstrated that activated
T-lymphocytes produce a TSH-like substance (Smith et al, 
1983). This substance might act as an immunogen that
triggered the production of TSH-binding antibodies and
consequently anti-idiotypic antibodies (ie anti-anti-TSH
antibodies), that could also bind to TSH receptors. 
Recently, monoclonal antibodies to the TSH receptor were
raised by an autoanti- idiotypic approach, by the immunization 
of Balb/c mice with bovine and human TSH (Hill and Erlanger,
1988). The binding to TSH of monoclonal antibodies obtained 
in this way, was inhibited by monoclonal antibodies secreted 
by Graves heterohybridomas. This finding suggested that 
there were similarities between the monoclonal anti-idiotypic 
antibodies and the Graves monoclonal antibodies. These 
results supported the idea that idiotypic network 
interactions may be involved in the pathogenesis of Graves 
disease.
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The use of hybridoma technology to produce different 
human autoantibodies from a complex disease such as Graves' 
disease thus demonstrates its potential in elucidating the 
pathogenic mechanisms involved in that disease.
2.1.6 Polyendocrine Autoimmunity
Human monoclonal antobodies have been prepared from 
patients with multiple endocrine disorders, and found to 
exhibit multiple-organ reactivity (Satoh et al,1983; Garzelli 
et al,1986). Satoh and coworkers reported the production of 
human monoclonal autoantibodies that reacted with tissues 
from multiple endocrine organs such as the thyroid, adrenal 
and parathyroid glands (Satoh et al, 1983). They isolated 9 
autoantibody-secreting hybridomas from 4 out of 20 patients 
with IDDM and a variety of autoimmune disorders. Two of 
these hybridomas produced antibodies against nuclear 
antigens; seven secreted antibodies that reacted with 
antigens in more than one endocrine organ; and several 
antibodies reacted with cytoskeletal elements in cultured 
human embryo fibroblasts.
One potential consequence of hybridoma techniques in 
studies of human autoimmune disorders is the possibility of
producing anti-idiotypic antibodies against the human
monoclonal autoantibodies obtained. Anti-idiotypic antibodies 
may serve as probes for detecting idiotopes that might be 
specifically expressed in particular autoimmune diseases.
Provided it were possible to produce human anti-idiotypic
antibodies, they might also be used as reagents for immune 
therapy to neutralize specific autoantibodies.
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Satoh and coworkers further characterized human 
monoclonal autoantibodies from the set of multiple organ 
reactive autoantibodies (Satoh et al, 1984). They found that 
MOR-hl, an IgM-k antibody, reacts with antigens in different 
organs including pituitary, thyroid, pancreas, and stomach. 
A MOR-hl-1inked immunoaffinity column isolated autoantigens 
of 35K and 21K molecular weight proteins with which the 
autoantibody reacts. The 21K mol wt protein was shown to be 
human growth hormone, whereas the 35K mol wt protein was 
present in the pituitary, thyroid and stomach.
Later, they reported the preparation and
characterization of three murine monoclonal antibodies 
directed against idiotypic determinants at or near the the 
paratope of MOR-hl. These anti-idiotypic antibodies reacted 
specifically with MOR-hl, and did not react with either 
pooled human myeloma IgM or 26 other monoclonal MOR 
autoantibodies. Using the three anti-idiotypic antibodies 
(4E6, 3E5, and 3F6), lymphocytes and sera from normal
individuals were tested for the presence of the idiotopes 
defined by them. The 4E6 idiotope was found on 1.17. of 
normal circulating B lymphocytes. 4E6 and to a lesser extent 
the 3E5/3F6 idiotopes were found on IgG molecules in normal 
sera. There was no increased expression of the 4E6 idiotope 
in sera of patients with several autoimmune diseases, as 
compared with normal controls, suggesting that anti-idiotypic 
antibody 4E6 recognizes a public idiotope whose expression is 
not restricted to autoimmune disease.
Despite the fact that Satoh and coworkers did not 
produce anti-idiotypic antibodies that identified idiotopes
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specific to particular autoantibodies, vital information may 
yet be provided by developing a large panel of anti-idiotypic 
antibodies directed against a spectrum of disease-specific 
monoclonal autoantibodies. It would then be possible to 
determine whether there were specific idiotopes expressed 
only on autoantibodies characteristic of a particular 
d i sease.
2.2 METHODOLOGY
2.2.1 Preparation of Human Hybridomas
The method chosen for the immortalization of human
lymphocytes was the inter-species cell fusion of the human
lymphocytes with a murine myeloma cell line. This was
achieved by using polyethylene glycol as the fusing agent 
(Pontecorvo, 1976). The methods for cell preparation, fusion 
and culture are described in the following section.
Preparation of Lymphocytes
The patient selected for the fusion experiment was a 
Caucasian male, age 35years, and diagnosed as a Type 1 
(insulin-dependent) diabetic. The patient had a strong
family history of diabetes mellitus, associated with thyroid 
disease. A serum sample from this patient was screened for a 
variety of autoantibodies to establish an autoimmune profile, 
(this was done at the Department of Immunology, Royal Surrey 
County Hospital, Guildford). At presentation of IDDM, this 
patient was positive for comp 1ement-fixing-1CA, IgG-ICA, 
anti-thyroid microsomal antibodies, and anti-thyrog1obu1in 
antibodies (Table 2.1).
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The method used for the preparation of lymphocytes from 
peripheral blood was developed by Boyum, and involved 
separation on the basis of density after agglutination of the 
red blood cells (Boyum,1968). It was found that lymphocytes 
could be isolated by layering diluted heparin-treated blood 
over a solution of Sodium metrizoate, containing a 
polysaccharide. Sodium metrizoate is a compound that is used 
extensively in density gradient separations. The
polysaccharide causes the erythrocytes to aggregate and 
subsequent low speed centrifugation (400g) pellets the denser 
erythrocytes leaving the lymphocytes as a well defined band 
at the interface of the two solutions.
100 mis of the patient's peripheral blood were drawn in 
a sterile manner into heparinized tubes. This was diluted 
1:2 in calcium and magnesium-free phosphate buffered saline 
(Flow Laboratories, Scotland). Lymphocytes were prepared by 
Pi C O  1 1 -hypaque centrifugation (Boyum,1968), using Lymphoprep 
(Nyegaard and Co, Oslo, Norway). Lymphoprep is a mixture of 
9.6% (w/v) Sodium Metrizoate and 5.6% Ficoll, an erythrocyte
aggregating polysaccharide.
4mls of the diluted blood were carefully layered upon 
3mls of lymphoprep in sterile 10ml centrifuge tubes, to avoid 
mixing. The blood and the lymphoprep thus formed a
discontinuous gradient, and the tubes were centrifuged (30-40 
mins, 18-20"C) at 400g at the interface between the blood and 
the Lymphoprep. The lymphocytes formed a band above the 
erythrocyte pellet and were removed using a sterile pasteur 
pipette. The cells were then washed twice in calcium and 
magnesium-free Hanks balanced salts solution (Gibco Ltd,
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Paisley, Scotland), by centrifugation (400g, 10 mins,
18-20"C). The cells were then resuspended and cultured in
10ml Dulbecco's modified Eagles medium (DMEM), supplemented
with 107. foetal calf serum (PCS), and 2mM glutamine,
penicillin lOOIU/ml and streptomycin lOOpg/ml (Gibco Ltd,
Scotland). Cell suspension was kept in a tissue culture 
flask (Nunc, Denmark) at 37*C in an atmosphere of 107. CO,, ^^
air (C0_, incubator, LEEC Ltd, Nottingham, UK). The total
cell count obtained was 70 x 10^ ' cells.
Cell Fusion Partner
The cell fusion partner chosen was the murine myeloma 
cell line P3-NS1/1-Ag4-1 (hereafter abbreviated as NSl),
(obtained from Burroughs Wellcome, Beckenham, UK). It is a 
non-secreting cell line that was derived from MÜPC-21, a 
BALB/c myeloma cell line. NS-1 does not express the MOPC-21 
gamma-1 heavy chain which would otherwise be incorporated 
into the hybridoma secretion product. It does, however, 
synthesize the original MOPC-21 kappa chain, but degrades it 
internally. The cell line is 8-azaguanine resistant and is 
therefore susceptible to HAT (hypoxanthine, aminopterin, 
thymidine)-selection (Littlefield, 1964). NSl cells have 
previously been fused successfully with human lymphocytes for 
the production of human monoclonal antibodies (Cote et al, 
1983; Boyd et al, 1984). The NSl cell line is thus suitable 
for fusion with human lymphocytes.
The NSl cell line was maintained in suspension culture 
in Dulbecco's modified Eagles medium (DMEM) supplemented with 
107. foetal calf serum, 2 mM glutamine, penicillin 100 lU/ml
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and streptomycin 100 pg/ml (Gibco, Paisley, Scotland). The
cells were grown in tissue culture flasks (Nunc, Roskilde,
Denmark) in a CO-:.? incubator maintaining an atmosphere of 107. 
CO,, in air. The tumour cells were maintained at a cell 
density of between 2 x 10™ and 5 x 10™ cells/ml. They were
subcultured every 2-3 days and fresh medium added.
In this procedure, polyethylene glycol was used as the 
fusing agent (Pontecorvo, 1976). Cell fusion is a random 
process and it is necessary to have a means of selecting the 
hybrid cells. After cell fusion, the heterohybridomas were 
selected by the method of Littlefield, which involves the 
culturing of the mixed population of fused and unfused cells 
in tissue culture medium containing HAT (Littlefield, 1964).
Aminopterin (an analogue of folic acid) blocks the de 
novo biosynthesis of purines and pyrimidines, and selectively 
kills the murine myeloma cells since they do not possess 
HGPRTase, an enzyme that is required in one of the salvage 
pathways of nucleotide biosynthesis. Culture medium
containing HAT (hypoxanthine, aminopterin, thymidine), 
however allows the growth of the hybridomas because they 
possess nucleotide biosynthetic salvage pathways that were 
derived from the fusion with the immune lymphocytes. The 
unfused human lymphocytes die in prolonged culture.
Freezing and Recovery of cells
Fusion partner and hybridoma cells were cryopreserved by 
the following procedure. Cells that were growing well (or in 
log phase growth) were spun down gently (200g, 5 mins) and
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resuspended in freezing medium, a mixture of 10% (v/v)
dimethyl sulphoxide (DMSO) and 90% (v/v) PCS. The cells were
resuspended at 1-5 x 10*''* cells/ml of freezing medium and 
aliquoted into 2 ml cryotubes (Nunc, Denmark). The cryotubes 
were placed in a styrofoam insulating box and placed in a
-70*C freezer overnight. The cryotubes were then transferred
to the gas-phase of a liquid nitrogen container (Union 
Carbide) for long-term storage. Recovery of cryopreserved
cells was done by rapid thawing of cryotubes in a 37*C 
waterbath. The thawed cells were carefully removed from 
cryotubes and carefully added to 30 mis of standard culture 
medium. The DMSO was then washed from the cells by
centrifugation (200g, 5 mins). The cell pellet was then
resuspended in culture medium and cultured in a tissue
culture flask, buffered in 10% COL», at 37"C as before.
Fusion Procedure
1) The human lymphocytes and NSl cells were mixed in a 
ratio of 10:1 (70 x 10*^'* lymphocytes to 7 x 10*^  NSl), and were 
pelleted in a sterile universal tube (Sterilin Ltd, UK) by 
centrifugation at 300g for 5 mins (benchtop centrifuge, MSE 
Scientific Instruments, Sussex, UK). The supernatant was
decan ted.
2) The cells were fused using 50% (w/v) polyethylene
glycol (PEG) 1500 (Sigma Chemicals, St Louis, USA), made up 
in serum-free Leibovitz medium L-15 (Gibco Ltd, Scotland).
Using a sterile 1 ml pipette (Sterilin, UK), 0,8 ml of 50% 
PEG were slowly mixed into the cell pellet over a period of 1 
min with continuous stirring for a further 1 min at room
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temperature. Then lOmls of serum-free Leibovitz L-15 medium 
were slowly mixed into the cell pellet mixture in 1ml 
aliquots over 5mins, to dilute out the PEG.
3) This suspension of cells was centrifuged at 300g for 
5 mins and the cells resuspended in 20 ml Dulbecco's MEM 
supplemented with 20% PCS and HT (hypoxanthine and 
thymidine), (Gibco Ltd, Scotland) and plated out into two 
24-well tissue culture plates (well volume 2 mis), (Nunc, 
Roskilde, Denmark). The culture plates also contained 
dispersed Balb/c murine thymocytes (lxlO™/ml) used as feeder 
cells. Each tissue culture well was topped up to about 2 ml 
with Dulbecco's MEM containing 20% PCS, 2mM glutamine, 
penicillin 100 lU/ml and streptomycin 100 pg/ml and HAT, 
(Gibco, Paisley, Scotland).
4) Pive days after the fusion, the aminopterin was 
diluted out from the cultures by feeding of the cultures with 
Dulbecco's MEM supplemented with 20% PCS and HT. This was 
repeated every four days or more frequently if culture medium 
became acidic.
5) Eighteen days after the fusion, the culture 
supernatants from wells containing visible hybridoma 
colonies, were tested for the secretion of human IgG and 
human IgM by a solid-phase immunoradiometric assay (IRMA). 
There were approximately 200 visible hybridoma colonies 
eighteen days after the fusion.
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Growth and Screening of Hybridoma Cultures
When hybridoma colonies were detected by eye (ISdays
after fusion), the supernatant fluids were taken and assayed
for production of human IgG and IgM by a solid-phase IRMA.
Cells from the positive secreting cultures were then cloned 
by limiting dilution into 96-well culture plates with feeder
layers of BALB/c murine thymocytes in Dulbecco's MEM with 20%
PCS. The remaining cells from the original positive wells in
the 24-well plates were cryopreserved by freezing at 5 x 10^ »
cells/ml of freezing medium (10% DMSO and 90% foetal calf 
serum) in 2ml cryoampoules (Nunc, Denmark) in liquid 
n i trogen.
The clones in the 96-well plates were grown to 
confluence and assayed for production of human IgG and IgM. 
Positive clones were expanded into 24 well (2 ml) plates and 
then into tissue culture flasks (surface area 25 cm^), (Nunc, 
Denmark), in which they were cultured in Dulbecco's MEM 
supplemented with 20% PCS. Supernatants were then harvested 
and stored at -20"C, in plastic 20 ml universal tubes 
(Sterilin Ltd, UK). Immunoglobulin secreting hybridomas were 
expanded and cryopreserved as described above.
2.2.2 Immunoradiometric assays for Human IgG and IgM 
The two assays used to screen for the secretion of human 
IgG and IgM in tissue culture supernatants of hybridoma 
clones were solid-phase immunoradiometric assays (IRMA). 
They involved the immobilization of affinity purified sheep 
antibodies to human immunoglobulins (IgG or IgM) onto a solid 
phase. In these assays, the solid phase was plastic tubes.
page 47
50-200 pi aliquots of tissue culture supernatant samples were 
incubated, and bound human IgG or IgM was detected by
subsequent incubation with radiolabelled second antibody,
washing and measuring bound radiotracer in a multigamma
coun ter.
Coating Buffer
The buffer used to coat the sheep antibodies to the 
plastic tubes was O.IM carbonate/bicarbonate buffer,
(pH 9.6) :
A) O.IM Na^cO^
B) O.IM NaHCO=
300 mis A added to 700 mis B and pH adjusted to 9.6. 
Washing Buffer
Phosphate buffered saline (PBS) + 0.27. bovine serum 
albumin (BSA, Sigma Chemical Co, St. Louis, USA):
8 g NaCl 
2.9 g Na=HPO*
0.2 g KCl 
0.2 g KH^fO*
This was made up to IL in distiled H=»0 and pH 
adjusted to 7.4. 0.17. sodium azide (BDH Chemicals,
Poole, UK) added as a bactericidal preservative.
Standards
Human IgG and IgM standards (Sigma, St Louis, USA) were 
diluted to set up assay standard curves in the range 
6-lOOng/ml diluted in tissue culture medium.
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Sheep Second Antibodies
Affinity purified sheep antibodies to human 
immunoglobulins were obtained from Guildhay Antisera, 
(Guildford, UK). Sheep anti-human IgG (HPS 901/1) and sheep 
anti-human IgM (HPS 1307/1) were used to coat plastic tubes.
Sheep Antibody lodinations
The affinity purified sheep antibodies to human IgG and
IgM were labelled with radioactive iodine (i=™l), using an 
adaptation of the Chloramine-T method described previously 
(Greenwood et al, 1963). This reaction can be used to 
radiolabel proteins to a very high specific activity. The 
reaction is virtually instantaneous and the time of contact 
between the protein and the potentially harmful oxidizing 
agent Chloramine-T should be kept to a minimum. The 
procedure was as follows:
1) 40 pg of immunoglobulin were dissolved in 20 pi 0.4 M 
Sodium phosphate buffer pH 7.4, and aliquoted into 
autoanalyser cups (20pl) to be used as the iodination 
vesse1s .
2) 0.4 mCi carrier free Na^-™! (Amersham, BUCKS, UK) were 
added to the immunoglobulin solution.
3) A solution of Chloramine-T (BDH Chemicals, Poole, Dorset, 
UK), 1.25 mg/ml 0.04 M Phosphate buffer was made up. The 
reaction was initiated by the addition of 10 pi of this 
solution to the iodination vessel and mixed for 15 
seconds using a Gilson 20pl adjustable pipette.
4) The reaction was stopped by the addition of 10 pi of a
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sodium metabisulphite solution (BDH Chemicals), 3mg/ml 
0.04 M Phosphate buffer.
5) The iodinated immunoglobulin was purified by gel 
filtration through a 1 x 10cm column of Sephadex G-15-120 
(Sigma, St Louis USA), pre-swelled in 0.1 M acetate 
buffer, pH 5.0. The column was eqilibrated with O.IM 
acetate buffer containing 0.57. human serum albumin. The 
iodination mixture was transferred to the column and 
eluted using 0.1 M acetate buffer containing 0.57. human 
serum albumin (Blood Products Laboratory, Elstree, Herts, 
UK) as carrier protein.
IRMA Protocol
The assays were set up according to a general protocol, 
as fo1 lows:
1) LP3 plastic tubes (Luckham Ltd, Sussex, UK) were coated 
with 200pl affinity purified sheep anti-human IgG or IgM 
second antibody (Guildhay Antisera, Guildford, UK) at 
Ipg/ml, using O.IM carbonate/bicarbonate buffer, pH 9.6 
overnight at 4*C. The tubes were aspirated and washed 
with phosphate buffered saline with 0.27. (w/v) BSA. These 
coated tubes could be stored at 4*C.
2) For the standard curves, human IgG or IgM standards (Sigma 
Chemicals, St Louis, USA) were used from 6-100 ng/ml 
diluted in Dulbecco's MEM (containing 207. PCS) and 200 pi 
of each standard sample were incubated in the precoated 
tubes at 37"C for 2hrs. Blank tubes (200 pi tissue
culture medium) were included in the assay to assess the 
non-specific binding due to serum. Tubes were again
aspirated and washed in PBS containing 0.057. (v/v) Tween
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and 0.27. (w/v) BSA. When hybridoma supernatants were
assayed, the sample volume used was 5-200p1, depending on
the volume of tissue culture fluid that could be removed
from culture plates.
3) Sheep antibody radiotracers were prepared by iodination of
affinity purified sheep anti-human IgG or IgM (as 
described above). The radiotracer antibodies were diluted
in PBS containing 0.057. (v/v) Tween and 0.2 7. (w/v) BSA,
and used at 50,000-100,000 CPM/200pl/tube. 200pl tracer
were incubated in the assay tubes for 2 hrs at 37*C. 
Tubes were aspirated, washed and counted for 
radioactivity in a multi-gamma counter (LKB Instruments, 
Croydon, UK).
2.2.3 Karyotyping of Cell Lines
Karyotype analysis of the murine myeloma and 
heterohybridoma cell lines was performed by conventional 
techn iques.
1) The cells of the hybridoma clones, as well as the NSl 
myeloma were cultured at 5x10^ cells/ml in Dulbecco's 
modified eagles medium containing 207. PCS (Gibco) in an 
atmosphere of 107. C0=. and 1007. humidity at 37*C.
2) To arrest mitosis in metaphase, the culture medium 
was replaced by Li ebov i t z med i urn L 15 containing 107. PCS and 
0.27. colchicine and incubated for 12 hours. Cells were then 
maintained in an atmosphere of 1007. humidity in air at 37'C.
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3) After this, cells were harvested by centrifugation at 
1,000 rpm for 10 min.
4) Chromosome "spreads" were made by allowing drops of 
medium containing cells, to fall onto glass microscope 
slides. It is important for the glass slides to be clean, 
grease free and ice-cold. 3 or 4 drops of cell suspension 
were allowed to fall onto a clean slide from a height of 
approximately 6 inches. Fixative was added to this and 
allowed to evaporate dry. The evaporation of the fluid 
causes the cells to rupture and the chromosomes spread out 
and adhere to the slide. The spread chromosomes were allowed 
to dry and age for two weeks.
5) When the slides were completely dry, the chomosomes 
were banded by digestion with freshly made 0.057. (w/v) 
trypsin dissolved in phosphate buffered saline, PBS (Ca^^ and 
Mg-'-"*^ free) for 5 to 10 seconds. The trypsin was washed off 
by rinsing in three separate baths of PBS (Ca--" and Mg-^) .
6 ) Finally the chromosome spreads were stained. The 
slides were covered with freshly prepared 0.37. aqueous Giemsa 
stain and left for 4 minutes.
7) The slides were drained and flooded with buffer pH 
6.8. The slides were then washed with tap water, drained and 
and left to dry.
8 ) When completely dry the slides were mounted in DPX 
and protected by a cover slip.
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2.2.4 Cellulose Acetate Membrane (CAM) Techniques
The introduction of cellulose acetate by Joachim Kohn
broadened the scope of applications of diffusion and
electrophoretic techniques. The main advantage of the use of
cellulose acetate membrane as a supporting medium is that it 
enables a high ratio of sample volume to cross section of
supporting medium, resulting in high sensitivity. Two CAM
techniques were used in the present study :
A) Ouchterlony Immunodiffusion
B) Immunofixation Electrophoresis 
MATERIALS AND BUFFERS
Barbitone Buffer (60mM, pH 8 .6 )
104g Sodium Barbitone
18.4g Diethyl Barbituric Acid
50 ml 5% Thymol in Isopropanol
The sodium barbitone and diethyl barbituric acid were 
made into a paste with the thymol. This was then dissolved 
slowly by the addition of distilled water and made up to lOL. 
The solution was shaken well and left overnight.
CAM Impregnating Buffer 
250 ml Barbitone Buffer 
1 ml Tween 20
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I mmunno-f i xat i on Buffer
200 ml Barbitone Buffer
8g Polyethylene glycol 6000
Nigrosin Stain
400 jjI saturated Nigrosin obtained from Raymond Lamb 
Ltd, UK, (made up in distilled water) is added to 200 ml 57. 
Acetic acid.
A . Ouchterlony Precipitin Technique
The Ouchterlony precipitin technique (Ouchterlony and 
Nilsson, 1978) (radial immunodiffusion technique) using 
cellulose acetate membrane (CAM) as the support (Kohn, 1976; 
Kohn et al, 1985) was used in the characterization of the 
monoclonal antibodies.
Cellulose acetate membranes were obtained from Sartorius 
Instruments (Sutton, Surrey, UK). The CAM was impregnated 
with barbitone buffer (60 mM, pH 8 .6 ). The tissue culture 
supernatants were set up in two immunodiffusion membranes, 
one using affinity purified sheep anti-human IgG and the 
other using affinity purified sheep anti-human IgM as second 
antibody (Guildhay Antisera, Guildford, UK). Positive
controls for human IgG and IgM were also set up on the CAM,
and the immunodiffusion was carried out overnight in a humid 
chamber. After this the CAM were washed in a solution of
3 % (w/v) NaCl containing 0.1%(v/v) Triton 405, and the
precipitation lines were made visible by staining with a 0.27. 
saturated solution of Nigrosin (Raymond Lamb, UK) in 57. (v/v)
acetic acid for 10 minutes. Tap water was used to destain 
the CAM.
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B. Immuno-f i xat i on Electrophoresis (CAM)
To determine the class type of the human monoclonal
antibodies, immunofixation studies using cellulose acetate
were performed (Kohn et al, 1985). The technique involves
electrophoresis of immunoglobulin on a cellulose acetate 
support, followed by overlaying the relevant part of the 
electrophoretic pattern with CAM impregnated with a 1st
antibody solution. Bound 1st antibody is then visualised by
staining.
Electrophoresis on CAM
1) 1 pi aliquots of hybridoma supernatants were applied
to CAM strips previously impregnated with barbitone buffer 
containing 0.4% (v/v) Tween 20.
2) The electrophoresis was carried out at 120 volts for 
1 hour in a humidity chamber.
3) The immunofixation step involved impregnating the 
strips with rabbit anti-light chain specific antisera (DAKO, 
Copenhagen, Denmark), using dilutions of 1/20-1/50, as 
foilows:
Pieces of CAM were cut to appropriate size for 
overlaying the paraprotein bands. These CAM overlays were 
impregnated in barbitone buffer containing 4% (w/v) PEG 6000 
and blotted. A small amount (10 pi per application) of each 
light chain-specific antisera was applied to a glass slide 
and the blotted CAM wet evenly in the antiserum. This was
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overlayed onto the paraprotein tracks on the strips and left 
for 5-10 mins.
4) The electrophoresis CAM was rinsed under tap water, 
washed twice in 37. saline containing 0.017. Triton for 30 
minutes each wash, and stained in nigrosin.
2.2.5 SDS-Polyacrylamide Gel Electrophoresis
SDS-Polyacrylamide gel electophoresis (SDS-PAGE), 
(Laemmli, 1970) was performed on the hybridoma supernatants 
from hybridoma cells that were metabo1ica 11 y labelled with 
" "*C- 1 eue i ne .
A . ’ ^ C-Leucine Metabolic Labelling
1) 50 X 10*'* hybridoma cells were washed twice with 10 ml
leucine-free minimum essential medium by repeated suspension 
and centrifugation (250g, 5 min).
2) The resuspended hybridoma cells were cultured at 5 x 
10"^  cells/ml in 10 ml leucine-free MEM supplemented with 107. 
dialysed, heat-inactivated foetal clf serum (Gibco)
3) 4 pCi/ml of i*C-leucine (Amersham, Bucks, UK) were 
added to the cell culture medium, mixed gently and the cells 
were cultured for 12 hours at 37*C in an atmosphere of 107. 
CO3 in air.
4) The culture supernatants and the cells were separated 
by centrifugation at 250g, for 5 mins and the supernatants
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were saved.
5)The cells were washed twice in ice-cold isotonic
sodium phosphate buffered saline and then lysed in 500 pi of
lysis buffer.
Lysis Buffer
0.1% (w/v) SDS
0.5% (w/v) sodium deoxycholate
1% Triton X-100
O.IM NaCl
10 mM sodium phosphate [NaPO*], pH 7.4
10 mM benzamidine.
These lysed cells were centrifuged at 100,000g for 60 
minutes at 4 "C and the supernatants were saved.
6)The antibodies were precipitated from the culture
supernatants and the cell lysates by incubation for 2 hours 
with a mixture containing:
i) Affinity-purified donkey anti-human IgG 
(1:10),(Guildhay Antisera, Guildford, UK)
ii) Human serum albumin (1:100) (Guildhay Antisera, 
Guildford, U K )
iii) 2% (w/v) polyethylene glycol 6000.
5)The precipitated antibodies were then dissolved in 
reducing buffer:
10 mM Tris-HCl pH 6.8
2% (w/v) SDS
5% (v/V)2-mercaptoethano1
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These samples were finally boiled for 1 minute, allowed 
to cool and run on a polyacrylamide gel using the method of 
Laemmli (1970), as described below. The gel was then fixed 
and autoradiographed.
B . SDS PAGE (Laemmli)
Acrylamide Stock 
30.Og Acrylamide
O.Sg NN'-methylene bisacrylamide 
Made up to lOOmls in distiled water.
1.5M Tris-HCl (pH 8.8)
18. 15g Tris dissolved in 50 mis HzO
pH adjusted to 8.8 with HCl
Made up to 100 mis in distilled H^O
0.25M Tris-HCl (pH 6.8)
3.0g Tris dissolved in 50 mis H%0
pH adjusted to 6.8 with HCl
Made up to 100 mis in distilled HraO
SDS PAGE PROCEDURE
1) The Separating (Lower) Gel was prepared:
10 mis Tris buffer pH 8.8
13.3 mis Acrylamide stock
Mixed well and made up to 40 mis with distilled H,,0 
This was degassed under vacuum
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2) 3% (w/v) agar was used to seal the gel moulding
plates. Polymerization of the separating gel was initiated
by addition of:
20pl N ,N ,N ',N '-tetra methy1ethy1ene diamine (TEMED) 
and 240p 1 10*/. ammonium persulphate solution.
400p1 of 10% (w/v) SDS solution were also added at this
stage, giving a final SDS concentration of 0.1% (w/v).
The gel solution was poured into the mould leaving a 4cm
space at the top of the mould. This was then overlayed with 
isobutanol and left to polymerize.
3) A stacking gel was polymerized above the separating 
gel. The composition of the stacking gel solution 
was :
2.5mls Tris buffer (pH6.8) 
l.Omls Acrylamide stock 
6. 5m 1 s distilled 
lOOpl 10% SDS solution
60p 1 10*/. ammonium persulphate solution
20pl TEMED
The isobutanol was washed from the polymerised 
separating gel, rinsed with 2mls stacking gel solution. The 
remaing space in the mould was filled with this solution. 
The plastic comb was pushed into the solution, ensuring that 
no air bubbles were trapped. After poymerization, the comb 
was removed carefully.
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4) When the gel had polymerized, it was clamped to the 
electrophoresis tank and the electrode reservoirs filled with 
electrode buffer.
The stock electrode running buffer (diluted 1:2 for use) 
had the following composition:
6.Og Tris base
20mls 107. (w/v) SDS solution
28.8g glycine
This was made up to ILitre with distilled H,,o
5) The precipitated immunoglobulin samples previously 
prepared for electrophoresis were carefully loaded into the 
wells in the stacking gel (60-70pl per well).
The electrodes were connected to the power pack (lower 
positive) and electrophoresed at 50 Volts (20 mA) for 30 mins 
and then at 180 Volts (60 mA) for 5-7 hours.
The gel was then removed and autoradiographed.
2.2.6 Immunohi stoc hemi stry
To further characterize the monoclonal antibodies, 
immunohistochemical staining of formalin-fixed tissues and 
unfixed fresh-frozen tissues were investigated. The
endocrine tissues studied were human thyroid, pancreas, gut, 
adrenal, pituitary, and testis. Staining on other
non-endocrine tissues was also investigated; these were
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breast, stomach, duodenum and colon.
Immunoperoxidase Staining (Heyderman, 1979)
The immunoperoxidase staining technique was used for
staining of formalin-fixed, paraffin-embedded tissue and is 
described as follows:
1) The tissue sections were dewaxed through 3 changes of 
xylene, and 3 changes of absolute alcohol to tap water, and 
r insed.
2) Acid heamatin was bleached with 6.07.
distilled water for 5 minutes. This was washed off with 3 
changes of tap water.
3) Endogenous peroxidase in the tissue sections was 
inhibited with 2.57. periodic acid in distilled water for 5 
minutes and washed with 3 changes of tap water.
4) Aldehyde groups were blocked with 0.027. potassium 
borohydride in distilled water for 2 minutes. 3 washes were 
made with PBS (pH 7.2) containing 0.027. sodium azide and 
Ipl/ml of detergent (1 7. BRIJ 96, Sigma Chemicals).
5) Hybridoma culture supernatants were concentrated 
tenfold using Amicon filters. After drying with blotting 
paper, sections were incubated overnight at 4 “C in a moist 
chamber with 40pl of concentrated hybridoma supernatants.
page 61
6) The samples were washed off with PBS-azide. Sections 
were agitated for 15 minutes in a bath of PBS-azide 
containing detergent. These were dried using blotting paper.
7) Horseradish peroxidase second antibody conjugate was 
diluted in PBS (azide free) containing 17. ovalbumin. 40 pi 
of this were incubated with tissue sections in a moist 
chamber for 60 minutes, and washed off with PBS-azide.
8) Sections were agitated in PBS containing detergent 
for 15 minutes.
9) A solution of diaminobenzidine (DAB) was made up, 
(10 mg DAB freshly dissolved in 10 ml 0.037. H%Oa in PBS). 
Sections were incubated in the DAB solution for 5 minutes and 
washed in tap water.
Indirect Immunofluorescence Staining
The method used for indirect immunofluorescence staining 
in this study was as follows:
1) Frozen sections of tissues were cut on a cryostat to 
5 pm thickness.
2) The sections were washed in Coon's 0.2 M barbitone 
buffer, pH 7.2.
3) Test samples (hybridoma supernatants concentrated 
tenfold) were applied and incubated overnight at 4"C.
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4) Samples were rinsed off in Coon's buffer (3 x 10 
mins).
5) F ITC-conjugated second antibody to human 
immunoglobulins (Sera Laboratories, Crawley Down, 
Sussex, UK) was diluted 1/50 in Coon's buffer and 
incubated with sections for 20 mins.
6) Sections were rinsed in Coon's buffer (3 x 10 mins)
7) Sections were mounted in non-fading mountant 
(Citifluor)
2.2.7 ^ -Up take Studies in FRTL-5 Cells
Thyroid-stimulating immunoglobulins have previously been 
detected in sera of Type 1 diabetics (Bliddal etal,1984). The 
ability of monoclonal antibody HML3.22 to stimulate or block 
thyroid activity was investigated. ^ *"™I-uptake studies in
FRTL-5 (Fischer rat thyroid line) cells were performed.
Fischer rat thyroid line (FRTL-5) cells are a continuous
line of functional rat thyroid epithelial cells that are able 
to accumulate inorganic iodide in a dose dependent manner 
when stimulated by Thyrotropin (TSH), or Thyrotropin receptor 
antibodies (TRAb),(the assay sensitivity is 5pU ml-* bovine 
TSH).
Stimulation of radioactive iodine uptake by the cells 
when incubated with immunoglobulin would be indicative of a 
stimulating TSH receptor antibody. TSH receptor blocking
antibodies are detected by their ability to inhibit TSH
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stimulated iodide uptake by the cells (Ambesi- Impiombato 
etal, 1980).
Two experiments were performed using monoclonal antibody 
HML3.22. Experiment 1 investigated the ability of the 
antibody to mimic TSH stimulation of iodide into FRTL-5 
cells, and experiment 2 investigated its ability to inhibit 
the TSH-stimulated uptake of iodide into the cells. The 
following experimental procedure describes how the effects of 
HML3.22 on FRTL-5 cells were tested.
Experimental Procedure
Day 1
FRTL-5 cells were plated out to a density of 2.5 x 10"‘Vml in 
24-well tissue culture plates, (0.5 ml suspension/we11 ; 5 x
10™ cells/well) and maintained for 3 days in Coon's modified 
Ham's F-12 medium containing a supplement of 6 hormones (6H) 
(i.e. including TSH).
Day 4
The medium was changed to Ham's F-12 medium containing a 5 
hormone supplement (5H) (i.e. without TSH)
Day 8
Cells were refed with fresh Ham's F-12 (5H)
Day 10
After a total of 10 days of culture the cells were used to 
assay thyroid stimulators and inhibitors. The test solutions 
were diluted in 5H medium and added to the cells.
page 64
Test Solutions 
Experiment 1
The monoclonal antibody supernatant was diluted 1/10 and 1/50 
in 5H medium and 0.5 ml aliquots of these and control 
solutions (containing no antibody) were incubated with FRTL-5 
cells for 48 hrs.
Experiment 2
The monoclonal antibody supernatant was diluted 1/10 and 1/50 
in 5H medium containing increasing doses of TSH (0,5,20, 100
pU /ml). 0.5 ml aliquots of these and control solutions
without antibody, were incubated with FRTL-5 cells for 48 
hour s .
Day 12
Test solutions were removed and replaced with fresh 5H
med i u m .
Day 13
After 24 hours in the fresh 5H medium the iodide uptake was 
assessed as follows (Weiss et al 1984). '5 H ' medium was
aspirated and 0.5 ml Hanks balanced salts solution (HBSS) 
containing 0.1 pCi carrier-free Nal*^™ and 10 pmol Nal/L to 
give a specific activity of 20mCi/mmol, was added. After 40 
minutes at 37*C the reaction was terminated by aspiratiom and 
washing with 1 ml ice cold HBSS To assess the amount of 
in the cells, 0.5 ml 957. ethanol was added to each well for 
20 minutes and then transferred to vials for counting.
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2.2.8 TSH Receptor Antibody Assay
Measurement of the thyrotropin receptor binding activity 
of the monoclonal antibody HML3.22 was made using an in vitro 
assay for TSH receptor antibodies adapted from the method 
described by Southgate et al (1984).
Ammonium sulphate precipitates of HML3.22 and HML3.21
media (6 ml) were redissolved in 0.3ml 20mM PBS (pH 7.5), and 
dialysed exhaustively against 20mM PBS pH 7.5. Dilutions of 
the antibody solution were then assayed in duplicate for TSH 
receptor binding activity.
50pl aliquots of samples were incubated for 30 mins with 
lOOpl solubilized porcine TSH receptors in lOmM TRIS, 50mM 
NaCl buffer (pH 7.5) containing 0.1% (w/v)BSA. 50p1
*^™I-bovine TSH (5000 cpm) were then added, mixed and
incubated overnight at 20'C. 800 pi of bovine TSH standard
(Thytropar, Armour Pharmaceuticals; Eastbourne, Sussex, UK) 
was added to the incubation mixtures. Receptor-hormone and 
receptor-antibody complexes were precipitated by addition of 
1ml 30% (w/v) polyethylene glycol 4000 in 1M NaCl (final
concentration 15% PEG). Tubes were mixed and centrifuged at 
15,000g for 60 mins at 4*C. Receptor-bound i^^^-TSH was
measured in the pellet.
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2.3 RESULTS
2.3.1 Human IgG and IgM Assays
Second Antibody Tracer Purification
The tracers for the assays were prepared by iodination 
of affinity purified second antibodies, sheep anti-human IgG 
and sheep anti-human IgM, using the Chloramine-T method as 
described in the methods section. lodinated antibodies were 
then purified by gel filtration through a column of Sephedex 
615-120. 3 ml fractions were collected. An example of a
purification profile of the iodinated tracers is shown in 
figure 2.1. The large peak at fraction 2 represents 
iodinated immunoglobulin, and the small peak (fractions 5-6) 
represents unincorporated *^^1.
Assay Sensitivity and Reproducibility
The detection sensitivity of both the human IgG and IgM 
assays were 5 ng/ml. The intra-assay precision for the IgG 
assay was 5.5% (n=10), and the inter-assay variation was 8%
(n=30).
2.3.2 Meterohybridoma Production
Peripheral blood lymphocytes from a diabetic patient 
were fused with cells ofthe murine myeloma NSl by the usual 
method, through mixing with polyethylene glycol (Pontecorvo, 
1976), as described in the methods section. Eighteen days
after the fusion, cell supernatants were removed for assays.
Day 18
The tissue culture supernatants from the 24 well plates
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after the fusion, cell supernatants were removed for assays.
Day 18
The tissue culture supernatants from the 24 well plates 
containing hybridomas were screened for the presence of human 
IgG and human IgM, using the solid phase IRMA. In total, 
there were approximately 200 visible clonies of hybridoma 
cells. It was found that 19 tissue culture wells contained 
supernatants with detectable levels of human IgG (>25ng/ml). 
None of the wells contained detectable levels of human IgM.
Day 21
The supernatant from one of these 19 culture wells, L3, 
contained >100ng human IgG/ml and contained distinguishable 
clones of cells. Two clones were picked and were expanded 
into wells of a fresh 24 well plate. Each well also 
contained 10'^  murine thymocytes, used as feeder cells. The 
culture wells were topped up to 2 ml with Dulbecco's medium 
supplemented with 107. PCS and HT.
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Table 2.1 Autoimmune Status of Type 1 Diabetic patient 
from whom Monoclonal Antibodies were derived
A n tib o d y  Type Titre
Anti-islet cell (complement fixing) 1:5120 (normal <  1:40)
Anti-islet cell (IgG) 1:5 120 (normal <  1:40)
Anti-thyroid microsomal 1:640  (normal <  1:40)
Anti-mitochondrial Negative
Anti-nuclear Negative
Anti-gastric parietal cell Negative
Tanned red cell anti-thyroglobulin 1:40 (normal <  1:40)
Sheep cell agglutination test for rheu­ Negative
matoid factor
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Fig 2.1 Example of a gel filtration purification profile 
for i^^I-labelled sheep anti-human IgG or sheep anti-human 
IgM, using a column of Sephadex 615-120. Column fractions
were eluted with O.IM acetate buffer, (pH 5.0) containing 
0.5% HSA. lodinated immunog1obu1inwas were eluted in
fraction 2, and unincorporated i==I eluted in fractions 5-6.
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Fig 2.2 Example of a standard curve for the IgG 
two-site IRMA (assay sensitivity 5 ng/ml).
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Day 30
Cell supernatants were screened for human IgG secretion. 
The supernatant in well L3.2 contained levels of IgG 
>100ng/ml. The cells in L3.2 were cloned by picking
individual colonies of cells and diluting into wells of
another fresh 24 multiwell plate with murine thymocyte
feeders (2 x lO^Vml). The other 18 positive wells had lower 
levels of IgG secretion, and colonies from these wells were 
also picked into wells of new 24 well tissue culture plates. 
IgG secretion was monitored for these colonies as they were 
expanded and cryopreserved.
Day 50
Wells L3.21 and L3.22 were found to contain the highest 
human IgG secreting clones (>100ng/ml) as detected by the 
solid-phase IRMA and both these wells of cells were recloned 
by limiting dilution into 96 multiwell tissue culture plates 
(with murine thymocyte feeders at 2 x lO^Yml).
The levels of secreted human IgG detected were in the
range 25-100 ng/ml, and the clones with the highest secretion
were cloned by limiting dilution into 96-well plates. The 
other cell clones were cryopreserved in liquid nitrogen. 
Cell lines HML3.21 and HML3.22 were found to be secreting 
human IgG in the region of lOOng/ml, and were stable for 11 
months. These cells were also cryopreserved and resuscitated 
check their stability.
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2.3.3 Karyotyping Study
To confirm that the HAT-resistant cell lines derived 
from the human-murine cell fusion were in fact human-murine 
heterohybridomas, karyotyping studies were performed with the 
two cell lines HML3.21 and HML3.22. These were compared with 
the karyotype of the murine myeloma NSl to assess the degree 
of incorporation of human chromosomes.
The karyotyping studies of the NSl cell line revealed 
the presence of chromosomes that were acrocentric, (the 
centromere is very close to one end of the chromosome). These 
chromosomes are characteristic of a murine origin (figure 
2.3). The chromosome spreads' of the hybridoma cells, 
showed a different karyotypic composition. They
demonstrated the presence of acrocentric chromosomes together 
with the consistent inclusion of additional metacentric (the 
centromere is located near the midpoint of the chromosome) 
and submetacentric (centromere is towards one end) 
chromosomes. These metacentric and submetacentric
chromosomes are typical of a human karyotype, and implied a 
human origin for these hybridomas (figure 2.4). Figure 2.4 
shows a typical chromosome spread from hybridoma HML3.22. 
These cells contained an average chromosome number of 82. 
Karyotype analysis revealed the consistent inclusion of 15 
metacentric and submetacentric chromosomes. These studies 
thus provided supporting evidence that HML3.21 and HML3.22 
were human heterohybridomas.
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Fig 2.3 Karyotype of the Murine Myeloma NSl, showing 
acrocentric chromosomes that are characteristic of a murine 
origin.
"a
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Fig 2.4 Karyotype of the Human - Murine heterohybridoma 
This shows the inclusion of metacentric and submetacentric 
chromosomes, characteristic of a human origin. 15 of these 
human - chromosomes have been identified and numbered.
13
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2.3.4 Immunodiffusion Study
In order to confirm the radioimmunoassay results which 
showed that the hybridoma clones were secreting human IgG 
immunoglobulin, supernatants of HML3.21 and HML3.22 were 
analysed in duplicate by Ouchterlony double immunodiffusion 
(f igure 2.5).
Both fusion supernatants as well as the human IgG
control formed precipitin lines against the sheep anti-human 
IgG second antibody spotted in the centre of the cellulose 
acetate membrane (CAM). No precipitin reaction was observed 
between the human IgM control and the second antibody, and 
this result confirmed that the heterohybridomas were 
secreting human IgG, rather than human IgM.
2.3.5 Immunofixation Study
The human immunoglobulins were further characterized by 
analysis of their light chain subclasses. This was achieved 
by immunofixation on cellulose acetate membrane CAM. The
anti-x-light chain second antibody did not cross-react with 
either HML3.21 or HML3.22 but the anti-k-light chain antibody 
reacted with both of the human monoclonal antibodies. This 
indicated that both immunoglobulins possessed k-light chains. 
An interesting feature of this technique is that it enables 
the detection of different monoclonal immunoglobulins on the 
basis of their electrophoretic mobilities. Thus, the 
different electrophoretic mobilities of the two monoclonal 
antibodies HML3.21 and HML3.22, suggested that they were
probably different antibodies with different binding 
specificities (figure 2.6).
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Fig 2.5 Ouchterlony Double Immunodiffusion on Cellulose 
Acetate Membrane (CAM). HML3.21 and HML3.22 were spotted in 
duplicate. Precipitin lines between the monoclonal antibodies 
and the anti—human IgG (central spot) confirmed that the 
monoclonal antibodies were human IgG. There was no reaction 
between the IgM control and anti-human IgG.
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Fig 2.6 Immuno-F i xat ion Electrophoresis Study of HML3.21 
and HML3.22. Both monoclonal antibodies possessed k-light 
chains. The different relative mobilities of the two
antibodies suggested that they were different antibodies.
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2.3.6 SDS-PAGE
Further characterization of the immunoglobulins was made 
by SDS-PAGE performed on metabo1ica11 y radiolabel led
antibodies secreted by the hybridoma cells. After fixing and 
autoradiography of the SDS-PAGE gel, it was found that in 
both HML3.21 and HML3.22, the relative mobilities of the 
three separated protein bands were approximately 15BkD, 52kD, 
and 20kD. These correspond to those of intact IgG, heavy and 
light chains respectively (figure 2.7), again confirmation 
that the immunoglobulins were IgG class. There were no 
immunoprecipitated bands observed in the NSl control lane.
2.3.7 Immunohistoe hemistry
The specificities of the two human monoclonal antibodies 
HML3.21 and HML3.22 were determined by immunohistochemical 
staining studies on various human tissues by immunoperoxidase 
staining as well as immunof1 ourescence staining.
Immunoperoxidase staining on various human tissues, 
including thyroid, gut adrenal and lung revealed staining 
only of the colloid within the thyroid follicles for HML3.21 
(figure 2.8). No staining of thyroid epithelial cells was 
observed. This suggested that the monoclonal antibody was 
binding to some colloidal determinant, possibly
thyrog1obuli n .
Immunohistochemical staining of HML3.22 was investigated 
for a vaiety of normal human tissues (Table 2.2). Strong 
indirect immunofluorescence staining of basolateral plasma 
membranes of thyroid follicle epithelial cells was observed 
for HML3.22. This monoclonal antibody did not bind to any 
other tissues tested.
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Fig 2.7 SDS-Polyacrylamide Gel Electrophoresis of 
immune precipitates from HML3.21 and HML3.22. Three distinct 
bands were precipitated from each hybridoma: Mr 158kD, 52kD, 
and 20kD, corresponding to intact human IgG, heavy and light 
chains, respectively. No immunoprecipitated bands were 
observed for the NSl control.
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Fig 2.8 Immunoperoxidase staining of human monoclonal 
antibody HML3.21 binding to colloid within thyroid 
follicles.
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Table 2.2 Immunohistochemical staining of normal human 
tissues using monoclonal antibody HML3.22
Tissue
Frozen
Section
Paraffin Wax 
Section
Endocrine tissues 
Thyroid
Epithelial cells + + +
Colloid — -
Stroma - -
Pancreas
Islet cells - :-
Exocrine cells — —
Stroma :- -
Adrenal
Cortex - -
Medulla - —
Testis
Germ cells — -
Leydig cells - -
Pituitary
Adenohypophysis —
Neurohypophysis — —
Nonendocrine tissues
Resting breast — —
Stomach - —
Duodenum — :-
Colon — —
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Fig 2.9 Indirect immunofluorescence staining of human 
monoclonal antibody HML3.22 binding to basolateral plasma 
membranes of thyroid follicle epithelial cells (frozen tissue 
sec t i on).
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2.3.8 i==I-Uptake Studies with HML3.22
HML3.22 was further characterized by i=«i-uptake studies 
into FRTL-5 cells. These rat cells are a commonly used 
system to assess the inhibition or stimulation of thyroid 
activity. The cell line is thus useful in studies of
autoantibodies to the TSH receptor such as those that are 
associated with Graves' disease.
Two experiments were performed, (figures 2.10 and 2.11). 
The first demonstrated that after a 48 hour incubation with 
FRTL-5 cells, the monoclonal antibody HML3.22 did not
stimulate iodide uptake (figure 2.10). The second experiment 
showed that following a 48 hour incubation, a 1/10 dilution 
of the monoclonal blocked all the TSH-stimu1ated uptake of 
iodide, while control cultures of FRTL-5 cells responded 
normally to TSH (figure 2.11). At a 1/50 dilution of 
HML3.22, TSH-stimu 1ated uptake of iodine was also inhibited. 
However, at this higher dilution of monoclonal antibody, 
lOOpU/ml of bovine TSH showed some stimulatory effect.
The results of these studies demonstrated that the
monoclonal antibody HML3.22 was binding to the TSH receptor 
in a manner that inhibited the stimulatory effect of TSH.
2.3.9 TSH Receptor Antibody (TRAb) Assay
The monoclonal antibody HML3.21 had been shown to bind 
to thyroglobu1 in (communication from Dr. Peter Byfield, 
Endocrinology Research Group, Clinical Research Centre, 
Harrow, Middx). Binding of HML3.22 to the TSH receptor was 
confirmed by the TRAb assay, and HML3.21 was used as a
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control. Increasing amounts of dialysed HML3.22 precipitated 
increasing amounts of i==i_TSH in the TRAb assay. The control 
HML3.21 showed precipitation in the range obtained for normal 
serum.
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Fig 2.10 Incubation of 1/10 and 1/50 dilutions of 
HML3.22 with FRTL-5 rat thyroid cells (48hrs) did not 
stimulate i=^l-uptake into the cells. The effect of HML3.22 
was similar to that of control tissue culture media.
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Fig 2.11 Inhibitor! of TSH-stimulated uptake into
FRTL-5 Cells by HML3.22. A 1/10 dilution of HML3.22 blocked 
TSH-stimulated uptake of at concentrations of bovine TSH
up to lOOpU ml
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Fig 2.12 Immunoprécipitation of ^=-"'l-TSH by monoclonal 
antibody HML3.22 in the TRAb assay. The control monoclonal 
antibody HML3.21 showed values that were in the range for 
normal sera.
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2.4 DISCUSSION
Human Monoclonal Antibodies to probe Autoimmunity in
Type 1 diabetes
The results of the present study have recently been 
reported (Tan et al, 1987). The aim of this study was to use 
hybridoma techniques to immortalize autoreactive B-cells from 
an insulin-dependent diabetic patient with multiple endocrine 
tissue autoimmunity. The successful use of the technique 
would assist in identifying autoantigenic determinants that 
were of pathogenic importance. Information would be yielded 
regarding whether common autoantigens are present in 
different tissue types, or whether tissue-specific 
autoantigens are predominant. Such information could throw 
light on the aetiology of these immunological disorders.
The autoimmune profile of the diabetic patient, prior to 
the fusion, indicated the presence of thyroid microsomal and 
thyroglobulin autoantibodies together with strongly positive 
titers of IgG-islet cell cytoplasmic antibodies, and 
complement-fixing islet cell antibodies (Table 2.1). In Type 
1 diabetes, there is an increased prevalence of 
autoantibodies to multiple endocrine tissue antigens (Drell 
and Notkins, 1987). The reasons for such immunological 
abnormalities are not known.
Following the fusion of murine myeloma NSl cells and 
peripheral blood lymphocytes from this diabetic patient, 
approximately 200 hybridoma colonies were obtained. 
Subsequent screening of tissue culture fluids detected human 
IgG secretion in 19 of the 48 culture wells. The levels of
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human IgG secreted were 25-50ng/ml in all the wells except 
one with hybridomas secreting >100ng/ml. Two distinct 
colonies were picked from this well L3, and subsequently 
expanded into two cell lines HML3.21 and HML3.22. These two 
hybridomas proved to be stable in culture. On the basis of 
their stability for immunoglobulin secretion, the monoclonal 
antibodies secreted by these two hybridomas were 
characterized. Karyotype studies confirmed that HML3.21 and 
HML3.22 were human-mouse heterohybridomas. The detection of 
human IgG secretion by the two-site IRMA was confirmed by 
Ouchterlony immunodiffusion. An immunofixation study
demonstrated that HML3.21 and HML3.22 both possessed k-light 
chains. Different relative mobilities of the two monoclonal 
antibodies in the immunofixation study suggested that the 
monoclonal antibodies were not from identical clones. An 
SDS-PAGE study of metabo1ica11y radiolabelled proteins from 
the two hybridomas, showed intact IgG, heavy and light chain 
protein mobilities. HML3.21 demonstrated immunohistochemical 
staining of colloid within thyroid follicles, whereas HML3.22 
stained thyroid follicle epithelial cells.
These immunohistochemical data suggested that HML3.21 
(in view of the patient's autoimmune profile, Table2.1) might 
bind to some colloidal antigen such as thyroglobulin, and 
that HML3.22 might target the TSH receptor. HML3.21 was 
subsequently found to target thyroglobulin by immunoassay. 
HML3.22 was found to cross-react with TSH receptors in a TRAb 
(TSH Receptor antibody) assay, and inhibited the stimulatory 
effect of TSH on a thyroid cell line.
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HML3.22 thus appeared to represent the thyroid 
inhibitory antibodies that bind to the TSH receptor, and that 
are -frequently associated with primary myxoedema, and are 
also detected in Graves disease (Valente et al, 1982). 
Hyperthyroid and hypothyroid diseases may be associated with 
Type 1 diabetes, and autoantibodies to thyroid antigens, 
including TSH receptor (Bliddal et al, 1984) have been 
detected in IDDM sera. The aetiology of these autoantibodies 
and their relationship to the appearance of islet cell 
autoantibodies is not understood. In diabetics with multiple 
autoimmunity, the pathogenic relevance of autoantibodies to 
tissue epitopes such the TSH receptor is unclear. However, 
an important finding in the present study was that the 
diabetic patient, initially euthyroid had later developed 
hypothyroidism (Tan et al, 1987).
The results of this study demonstrate that by
successfully immortalizing human B- 1ymphocytes it is possible 
to study immunoglobulins that are associated with islet cell 
antibodies, in Type 1 diabetes, but that are present in low 
titers. A number of technical problems accompany the 
production of stable human hybridomas. Although somatic cell 
hybridization is presently the most commonly used technique 
to immortalize cells, it is still a non-specific technique.
The fusion of two cell types is not a precise process
involving a cell of one cell line with a cell of another cell 
line. Instead, multiple fusions (fusions of more than two 
cells) may take place involving different permutations of 
cells from the two cell lines. The lack of widely used 
suitable fusion partners and the genetic instability of
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inter-species hybrids hinder progress in this -field. This 
may account -for the small number of human immunoglobulin 
secreting hybridoma colonies obtained in this study, as well 
as their relatively low secretion levels. However, the 
successful derivation of stable cell lines secreting human 
immunoglobulin, provides a tool with great potential to probe 
the immune system and identify the variety of epitopes 
targeted.
Multiple Organ Autoimmunity
The production of autoantibodies specific for thyroid 
antigens, derived from peripheral blood lymphocytes of a 
newly diagnosed diabetic patient, indicates the complexity of 
the autoimmune phenomena. Satoh and coworkers (1983) have 
reported evidence that autoimmune phenomena in p o 1yendocrine 
disorders may involve autoantigens common to a variety of 
endocrine tissues that mediate the autoimmune response. This 
was done by preparing hybridomas from lymphocytes of patients 
with multiple autoimmmune abnormalities. They produced 9 
secreting hybridomas, 7 of which secreted monoclonal 
antibodies that were found to react with antigens in multiple 
endocrine organs.
In a subsequent study Garzelli and coworkers identified 
clones of EBV-transformed human lymphocytes that secreted 
human monoclonal autoantibodies reacting with human islet as 
well as thyroid antigens (Garzelli et al, 1986). They 
derived six cell lines from lymphocytes of one patient with 
diabetes, three patients with both diabetes and thyroiditis 
and one with hyperthyroidism. All six monoconal antibodies
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were -found to react with pancreas islets and thyroid acinar 
tissue. Some of the monoclonal antibodies were also found to 
react with other tissues such as peripheral nerve axon; one 
reacted with esophagus cell border and another with 
T-1ymphocytes.
The derivation of mu 11ip1 e-organ reactive autoantibodies 
is significant in that it may provide an explanation for the 
mu 11ip1 e-organ reactivity found in serum of diabetics. 
However, it does not mean that organ specific autoantibodies 
are not present in such patients. The results of the study 
described in this chapter do not support the idea that all 
mu 11ip1e-organ reactivity in autoimmune serum is due to 
multiple reactive antibodies, since the monoclonal antibodies 
HML3.21 (anti-thyrog1obu1in), and HML3.22 (anti-TSH receptor)
only reacted with thyroid antigens when screened against a 
number of tissues. No staining was observed against 
pancreatic cells. Instead, the results suggest that the 
autoimmune phenomena involved in po 1yendocrinopathies are
complex, and may involve the production of either 
multi-organ reactive or organ-specific autoantibodies.
The evidence proposed by Satoh and Garzelli and their 
respective coworkers is not conclusive and more information 
is needed to clarify the nature of the autoimmune response, 
and to differentiate between the two possible processes. In 
this way will it be possible to elucidate their precise
pathogenic involvement. The continued use of hybridoma
techniques would enable the dissection of the autoimmune 
phenomena and ultimately lead to the greater understanding of
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these processes.
Autoantibody Assays
The current assays used -for the detection of islet cell 
cytoplasmic autoantibodies (ICCA), and islet cell surface 
antibodies (ICSA) are indirect immunofluorescence staining on 
human pancreatic sections and immunoassays using whole cells, 
respectively. The immunofluorescence test is not a 
convenient tool for the routine screening of monoclonal 
antibodies in tissue culture supernatants, and for the 
present study a suitable substrate for screening islet cell 
surface antibodies was not available. Rapid and reliable 
assays for the screening of thyroid antigens were also not 
available. Since the objective of the study was to isolate a 
range of cell lines secreting human antibodies, whatever 
their specificities, an immunoassay for human immunoglobulin 
was the choice for a first-line screen for the hybridoma 
supernatants.
The continued use of hybridoma techniques to immortalize 
rare B-cell specificities, may assist in revealing the 
presence of hitherto undetected autoantibodies associated 
with an autoimmune disorder. The development of more 
specific and sensitive assays would assist in the screening 
of hybridomas secreting specific autoantibodies and studies 
into the pathogenetic roles of autoantibodies to endocrine 
tissues such as thyroid and islet cell may be taken further. 
Such studies would eventually determine whether the detection 
of these autoantibodies could be used as markers of the onset 
of a pathogenic process that would lead to clinical
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disorders. With regards to the characterisation of the 
offending islet autoantigens involved in diabetes, human 
monoclonal antibodies to the islet cells would assist in 
their purification and subsequent use as targets in specific 
immunoassays for islet cell antibodies.
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CHAPTER 3
DEVELOPMENT OF ASSAYS FOR 
ISLET CELL SURFACE ANTIBODIES
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Chapter 3: Development of Immunoassays for Islet Cell
Surface Antibodies
3.1 INTRODUCTION 
The presence of autoimmune islet cell antibodies (ICA) in the 
sera of insulin-dependent diabetic subjects was reported in 
1974 (Bottazzo et al 1974; MacCuish et al 1974). Subsequent 
studies have found an association of the autoantibodies in 
most individuals with type 1 diabetes mellitus (Bright et al 
1982; Drell and Notkins, 1987). There has been increasing 
evidence that these autoantibodies may have a pathogenetic 
role in the aetiology of IDDM, as well as being markers of 
the disease (Bottazzo et al 1984; Drell and Notkins, 1987).
a ) Cytoplasmic ICA
Cytoplasmic ICA are so named because they appear to bind 
some poorly understood cytoplasmic antigen(s) in the 
pancreatic islets. These autoantibodies are detected in 
human sera by indirect immunofluorescence staining (IIP) on 
human pancreatic tissue sections, (Bottazzo and Gleichmann, 
1986), and large studies of the incidences of (cytoplasmic) 
ICA are currently being performed using this assay technique 
(Kolb et a l , 1988).
Indirect Immunofluorescence Staining
The indirect immunofluorescence staining technique (IIP) 
for the detection of islet cell cytoplasmic antibodies (ICCA) 
is now widely used. However, the technique has some 
disadvantages. The assay may depend on the subjective
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observations of the operator,in the assessment of negative 
and positive readings, although there have been recent 
developments in quantitative immunof1uorescent staining 
methods (Bright, 1987). Also, the accuracy of the technique 
may be affected by the variability from one batch of 
pancreatic tissue sections to another. In the absence of 
international control sera, the readings for the IIP 
technique are arbitrary. There have been recent attempts at 
standardization of the assay technique and studies of its 
reproducibility between various laboratories (Bottazzo & 
Gleichmann, 1986; Bonifacio et al, 1987). At the first 
meeting of the international workshop on the standardization 
of cytoplasmic islet cell antibodies, there was disagreement 
between the participating laboratories, about the end-point 
titers of many of the test sera as well as whether some were 
positive or negative (Bottazzo and Gleichmann, 1986). There 
are no international reference sera for ICA yet, although 
attempts are being made to evaluate standard sera, as well as 
a common means of designating titer units to assay results 
(Bottazzo and Gleichmann, 1986; Bonifacio et al 1987). The 
development of alternative assay methods that are rapid, 
more specific and reproducible than IIP would assist in the 
large scale screening of sera from diabetic and healthy 
control patients. Although the IIP technique most easily 
detects autoantibody reactivities to the cytoplasm of islet 
cells, surface autoantibodies may also be present. Assays 
have been developed to differentiate these antibodies.
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b > Cell Surface ICA
The second type of islet cell antibodies are called 
islet cell surface antibodies (ICSA) which appear to bind 
some poorly understood antigen(s) on the cell surface. These 
autoantibodies have been detected by using viable pancreatic 
islet cells or islet tumour cells as targets in immunoassays, 
where they are found to bind to the surface of these 
pancreatic cells. Examples of these are a radioassay using 
viable rat islet cells and i=:=I-Protein A (Huen et al, 1983), 
ELISAs using rat islet cells (Sai & Maurel, 1983), and a rat 
insulin-secreting cell line RINm5F (Laborie et al, 1985), and 
an immunoradiometric assay using live transformed islet 
cells as targets with ^^“’"I- 1 abe 1 1 ed second antibodies as 
tracer (Contreas et al, 1986).
When the principal autoantigens responsible for 
cytoplasmic ICA and cell surface ICA are characterized, so 
will more specific assays for these two apparently different 
autoantibody types be developed. The development of reliable 
and rapid detection systems for these autoantibodies would be 
very important for prospective studies of individuals who are 
in high-risk (prediabetic) groups for developing Type 1 IDDM. 
The assays would also be important tools for the quantitative 
monitoring of islet cell antibody levels after the onset of 
disease. The following chapter describes the development of 
two assay methods for the detection of islet cell surface 
antibodies. These methods may be used for the detection of 
autoantibodies present in human sera. The assay methods may 
also be used for the detection of islet cell autoantibodies 
secreted by hybridoma cells derived from lymphocytes from
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diabetic patients.
3.1.1 Insulin-Secreting Rat Cell Line RINmSF
The assays described in the following sections involve 
the use of an insulin-secreting rat cell line RINmSF 
(Gazdar et al,1980) originally derived from a transplantable 
radiation-induced rat islet cell tumour (Chick et al,1977). 
The cell line was kindly provided by Dr. A.J. Bone, (Western 
General Hospital, Edinburgh, U.K.) by courtesy of Professor 
C. Hellerstrdm (Uppsala, Sweden).
There have been extensive studies in the development of 
in vivo models of insulin-induced hypog1ycaemia that make use 
of transplantable insulin-secreting cell tumours. The 
serially transplantable rat insulinoma (Chick et al, 1977) 
has been increasingly adopted for studies in insulin 
secretion (Sopwith et al, 1981; Hutton et al, 1984; Flatt and 
Swanston-F1att,1985). The establishment of an
insulin-secreting cell line RINmSF from this transplantable 
tumour (Gazdar et al,1980) was a significant development in 
that it made available large amounts of cells that could be 
used in studies of various aspects of pancreatic B-cell 
fune t i on .
RINmSF cells have been used extensively in studies of 
insulin secretion (Wollheim and Pozzan, 1984; Praz et al, 
1983). In a recent study, this cell line demonstrated 
insulin secretory responses to a variety of established 
B-cell secretogogues (Flatt et al, 1987). These responses 
suggested similarities between the secretory properties of 
these cells and normal B-cells. One major difference is that 
their insulin content is only about 1 % of that of pancreatic
page 100
B-cells (Flatt et al,1987; Glyfe et al,1983;Praz et al,1983).
More recently, these cells have been used as targets in 
the detection of islet cell surface antibodies (Eisenbarth et 
al, 1981a; Laborie et al, 1985). Eisenbarth and co-workers 
demonstrated the binding of cytotoxic antibodies in human 
sera to RINmSF cells, suggesting the presence of some as yet 
uncharacterized islet cell surface autoantigen on these 
cells that are similar to those found in human islet cells. 
These cells have also been used by other workers to assay 
ICA secreted by clones of hybridoma cells (Garzelli et 
al,1986).
The RINmSF cell line used by Flatt and coworkers 
contained 0.56ng insulin/10^ cells, compared with tumoral rat 
insulinoma cells which contained 156pg insulin/10^ cells 
(Flatt et al, 1987). It has been suggested that the small 
amounts of insulin content of cell lines such as these, are 
due to progressive loss after their long-term culture in 
vitro. This particular RINmSF cell line was chosen for use 
in the development of the immnoassays for ICSA described in 
this chapter. The low amounts of insulin in these cells
would help to reduce the possible cross-reactivity with any 
insulin autoantibodies present in the diabetic sera being 
assayed. Insulin autoantibodies are often found together 
with islet cell antibodies in the sera of Type 1 diabetics
(Better le et al, 1987).
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3.1.2 Immunoassays for ICSA
Cell-Binding Immunoradiometric Assay (IRMA) for Islet
Cell Surface Antibodies
A fundamental requirement for the development of a rapid 
and reproducible immunoassay for ICSA is the availability of 
a reproducible antigen target. Existing assays for ICSA have 
made use of human and rodent islet cells as targets. More 
recently, assays using insulin-secreting cell lines have been 
developed because of the technical advantages of culturing 
islet cell lines, over the routine preparation of viable 
islet cells from pancreatic tissue (Gazdar et al, 1980). A 
number of radioassays for ICSA have previously been
developed, using rodent islets (Huen et al, 1983) and RINmSF
cells (Flatt et al, 198S) as targets, and ^^^I-Protein A to 
detect bound autoantibodies. Immunoradiometric assays have 
been in existence for many years, (Hales and Woodhead, 1980), 
and have been applied in solid-phase assays involving 
cell-bound antigens. An immunoradiometric assay has been 
developed for islet cell surface antibodies, using an islet 
cell line MSL-G2-Tu6 and iodinated second antibodies 
(Contreas et al, 1986). This assay was used to detect ICSA 
in sera from non-diabetic and diabetic BB (Bio Breeding) rats 
as well as murine hybridoma supernatants. The cell-binding
immunoradiometric assay for ICSA described in the following
study used the insulin-secreting RINmSF cell line and 
iodinated second antibodies to human IgG.
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Enzyme-Linked Immunosorbent Assay (ELISA) for Islet Cell
Surface Antibodies
Enzyme linked immunsorbent assays (ELISA) represent the 
most successful developments in immunoassay systems that use 
non-radioactive labels. They relpace the use of
radioisotopes with enzymes. Enzyme-labeled antiglobulins 
were used in ELISAs first described by Van Weeman and Schuurs 
(1971, 1972) and Engvall and Perlmann (1971, 1972). Since
then the applications of the procedure have expanded rapidly 
(Voiler et al, 1979; Voiler and Bidwell, 1980).
ELISAs using viable as well as fixed whole cells for the 
detection of islet cell surface antibodies have been in 
existence for some years (Sai et al,1983; Laborie et
al,1985). ELISAs using whole cells as targets have been 
developed for the screening of monoclonal antibodies
(Douillard et al, 1980). Garzelli and coworkers (1986) used
their cell ELISA (using RINmSF cells) to screen human
hybridoma culture supernatants. The aim of the present study 
was to develop a rapid ELISA system that would provide
distinct advantages over the existing assay systems for ICSA. 
The use of existing cell surface immunoradiometric assays or 
ELISAs in microtiter plates involves the routine large-scale 
culture of target cells and the need for reproducible
attachment of these cells onto the plastic plates. This
poses potential problems of intra-assay and batch-to-batch 
variations since the cell numbers seeded into the wells may 
not be uniform and the cells may not remain attached to the 
wells uniformly throughout the assay procedure. The use of 
attachment factors such as poly-lysine to enhance cell
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attachment to plastics may lead to high background signals, 
and the fixation of bound cells (to preserve cells for
long-term storage) may alter some cell surface antigens being 
targeted.
The following sections describe the development of two 
immunoassays for ICSA: a cell-binding immunoradiometric assay 
(IRMA), and an ELISA using islet cell membrane antigens.
Both assays make use of the rat insulin-secreting RINmSF cell
line. The cell IRMA was developed first, in order to obtain 
ICSA positive IDDM serum samples. These were then used in 
the development and assessment of the ELISA.
3.2 METHODOLOGY
The following sections describe the materials and
methods that were used in the development of the cell-binding 
IRMA, and the ELISA for ICSA.
Buffers for Assays
Phosphate Buffered Saline (PBS), pH 7.4, 0.15 M
8 g NaCl
1.15 g Na^HPO*
0.2 g KCl 
0.2 g KH^^o*
Made up to 1 litre in distilled water.
ELISA Buffer : PBS + Gelatine -+- Tween (PBS-GT)
PBS made as above. To 1 litre of PBS the following were 
added :
1 g Gelatine
500 pi Tween-20
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Citrate-Phosphate Buffer pH 5.3 (for ELISA)
4.67 g Citric acid
7.29 g Na^^PO*
This was made up to 1 liter with distilled water and the
pH adjusted to 5.3. The buffer was stored at 4 “C.
Culture and Maintenance of RINm5F Cells
RINm5F cells were grown in monolayer culture in plastic 
tissue culture flasks (125 cm=) (Nunc, Roskilde, Denmark) in 
tissue culture medium RPMI-1640 supplemented with 107. foetal 
calf serum, 2mM glutamine, penicillin lOOIU/ml and 
streptomycin lOOpg/ml (Gibco, Paisley, Scotland). Each 125cm-- 
flask contained 40-50 mis culture medium. The cells were 
cultured at between 1 x 10" and 4 x 10" cells/ml at 37"C in
an atmosphere of 57. CO-, in air in a CO^^incubator (LEEC Ltd,
Nottingham, UK). For the expansion of RINm5F cells in 
culture, confluent monolayers of cells were detached from the 
flasks and resuspended in single-cell suspension by the 
following method:
1) Tissue culture medium was poured off from the tissue 
culture flasks, and the cell monolayers were gently rinsed 
with 10 mis Ca-- " and Mg^^-free Hanks Balanced Salt Solution 
(Ca/Mg-free HBSS), (Gibco). The HBSS was decanted.
2) The cell monolayers were then rinsed in 10 mis of
Ca--'*' and Mg^^-free PBS (Gibco) containing 0.1257. trypsin and 
0.027. EDTA (Gibco). This was decanted leaving 2-3 mis of 
solution in the flasks which were then incubated at 37"C for 
5 minutes, to allow the cells to detach.
N.B. Cells that were to be used in the ICSA assays were
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detached by washing and incubation with 0.027. EDTA in PBS. 
Trypsin was omitted from the detachment solution to prevent 
any proteolytic effects that trypsin might have on the cell 
surface antigens being targeted by autoantibodies.
3) Detached cells were resuspended in 10 mis of fresh 
tissue culture medium as a single-cell suspension. These 
were reseeded into new tissue culture flasks at a 1:5 
dilution. The cells were subcultured at a 1:5 dilution every 
3-4 days.
4) Cells that were harvested for use in the cell-binding 
radioassay were washed twice by centrifugation in Ca/Mg-free 
PBS (200g, 5mins), (benchtop centrifuge, MSE Scientific 
Instruments, Sussex, UK). The cells were counted using a
haemocytometer and used immediately.
Cell Counting and Determination of Viability
The surface membrane of living cells is able to exclude
certain dyes, whereas dead cells permit these dyes to enter
easily. The cells were counted and their viability
determined by trypan blue exclusion (Tennent, 1964). lOOpl
of a 0.27. solution of trypan blue (Flow Laboratories, 
Scotland) was mixed with lOOpl of cell suspension at
dilutions 1/10 and 1/100, and left to stand for 5-10 mins.
The cells were counted in five large squares of a 
haemocytometer chamber to determine the mean counts and the 
percentage cell viability was calculated by the formula:
Number of viable cells  x lOOX
Sum of viable and dead cells
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RINm5F Membrane Preparation
1) RINmSF cells were grown in tissue culture as 
described above. Cells were detached from the plastic tissue 
culture flasks by rinsing with PBS, and then rinsing with 
PBS containing 0.027. EDTA. The cells were washed twice with 
PBS by centrifugation (200g for Smins), (benchtop centrifuge, 
MSE, Sussex). Cells were then stored at -20*C in PBS
contaning lOmM benzamidine (Sigma) and 0.17. sodium azide.
200 X 10"^ = cells (>957. viability) were used for each 
solubilized membrane preparation.
2) Cells were thawed and centrifuged at 300g for 10 mins 
at room temp (benchtop centrifuge, MSE Scientific 
Instruments, Sussex, UK). The cells were resuspended in 20 
mis distilled H-.0 containing 10 mM benzamidine and were mixed 
gently. This was allowed to stand for 10 mins to lyse the 
cel Is.
3) Lysed cells were centrifuged at 600g for 10 mins at
4*C, (large plasma membrane fragments located in the pellet). 
The pellet was washed twice by centrifugation at 10,000 g for 
10 mins, 4*C, in 20mls PBS containing lOmM benzamidine (J2-21 
centrifuge, rotor JA17, Beckman Instruments Ltd).
4) The pellet was solubilized by mixing with 2 ml of PBS 
containing 17. Triton X-100 (BDH Chemicals Ltd, Dorset, UK), 
lOmM benzamidine and 0.17. azide. This was kept at 4°C for 
1 hr with gentle mixing every 15 mins. The mixture was 
centrifuged at 100,000 g for 30 mins at 4"C to remove any
insoluble material (L5-65B Ultracentrifuge, rotor TY65, 
Beckman). The supernatant was centrifuged again as before,
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and the pellet discarded. The supernatant was stored at 4*C 
until use in the islet cell ELISA.
Collection and storage of serum samples
Serum samples were collected by allowing blood samples 
to clot, detaching clots, and centrifuging the serum (1500g 
for 15 min at 4°C), (J-6B centrifuge, Beckman Instruments,
UK) to remove remaining cells. Serum samples were preserved 
with 0.17. sodium azide. To avoid nonspecific binding of sera 
to rat antigens, serum samples were adsorbed against rat 
liver acetone powers (Huen et al, 1983). 1ml of serum 
samples were heat-inactivated (56*C, waterbath for 30 mins) 
and incubated overnight at 4*C, with 100 mg of rat liver 
acteone powder (Sigma, St.Louis, USA). The rat liver acetone 
powders were washed just before use, by making a lOOmg/ml 
suspension in PBS containing 0.57. BSA, and centrifuging 1ml 
aliquots of this in LP3 tubes (Luckham Ltd, Sussex, UK), 
(2500g, 30 mins, 4 “C). Adsorbed serum samples were
centrifuged (2500g, 30 mins) and serum collected. Adsorbed
sera were stored at 4 "C before assay.
lodination and Purification of affinity-purified sheep 
ant ibodies
Affinity-purified sheep antibodies to human IgG and 
human IgM were obtained from Guildhay Antisera Ltd, 
Guildford, UK. These sheep antibodies to human IgG were 
labelled with ^--"iodine (Amersham International, U.K.) using 
an adaptation of the chloramine-T reaction method according 
to Hunter and Greenwood (1962). The iodinated sheep
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immunoglobulins were then purified by gel filtration using a 
1 X 10 cm column of Sephadex G-15-120 (Sigma, St Louis, USA), 
as described in section 2.2.2.
Enzyme-labelled conjugates
Horseradish peroxidase-labelled sheep antibodies to
human IgG were obtained from Guildhay Antisera Ltd,
Gu iIdford.
3.2.1 Cell Immunoradiometric Assay
IRMA Procedure
The assay buffer used, was phosphate buffered saline
(PBS) containing 0.57. bovine serum albumin BSA (Sigma).
All samples in the cell IRMA were assayed in duplicates.
1) A 100 pi aliquot of resuspended RINm5F cells (10^ 
cells/ml) was incubated with 100 pi of serum sample dilutions 
made in assay buffer. The samples were mixed with the cells 
and were incubated for 2 hrs at 3 7 “C in LP3 plastic tubes 
(Luckham Ltd, Sussex, UK). Cells were washed once by 
addition of 1 ml of assay buffer and centrifugation at 200g 
for 10 mins (J-6B centrifuge, Beckman Instruments, UK).
2) 200 pi of tracer, 100,000 cpm/tube (iodinated sheep 
anti-human immunoglobulins) were mixed with cell pellet and 
incubated for 2 hrs at 37*C. The cells were washed once by 
the addition of 1 ml of assay buffer, and centrifugation at
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200g for 10 mins.
Finally the assay tubes were counted for radioactivity 
in a gamma counter (LKB Instruments, Croydon, UK) to
determine the amount of bound radioactivity.
Assay of ICSA in human IDDM serum samples by Cell IRMA
In order to obtain positive and negative sera for ICSA, 
a series of 32 serum samples from recently diagnosed
insulin-dependent diabetic patients (< 3 months), and 20
serum samples from healthy non-diabetic individuals were 
screened using the preliminary cell IRMA, prior to its
optimization. Positive and negative sera obtained could 
thus be used in optimization studies of the assay. Serum 
samples were assayed at dilutions of 1:20 and 1:80 in the
cell IRMA as described in the assay protocol above. After 
the cell IRMA had been optimized, dilution curves were
obtained for the 32 IDDM serum samples as well as the 20 
non-diabetic serum samples (dilutions 1:10, 1:20, 1:40, 1:80,
1:160).
Control Cell Lines
In order to check that immunoglobulins in the diabetic 
sera tested, were not binding to non-specific cell surface 
antigens present on non-pancreatic cells, two control cell 
lines were used as targets. The murine myeloma
P3-NS1/1-Ag4-1 (abbreviated as NSl), and the murine 
fibroblastoid 3T3 cell lines were cultured as suspension, and 
monolayer cultures respectively. The culture medium was the 
same as that used for RINmSF cells, RPMI-1640 medium 
supplemented with 107. foetal calf serum, 2mM glutamine,
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penicillin lOOIU/ml and streptomycin lOOpg/ml (Gibco, 
Paisley, Scotland). Since the NSl cells were free-floating, 
it was not necessary to treat them with trypsin or EDTA to 
detach them from the tissue culture flasks. The 3T3 cells 
were processed by the same procedure as for RINmSF cells. 
All sera tested against RINmSF cells were reassayed at a 
dilution of 1:20, for binding against NSl or 3T3 cells, using 
the same assay procedure and cell numbers.
Optimization of Cell numbers in IRMA
A study was performed to determine the optimum number of 
cells per assay tube. Cells were prepared and counted for 
the assay as described, and doubling dilutions of cell 
numbers were made from 80 x 10" to 0.1S6 x 10" cells per 
tube. The positive and negative control sera (obtained from 
the initial screen), were incubated with cells at a dilution 
of 1:20.
Variation of sample and tracer incubation periods
A study to assess the optimum sample incubation time was 
performed. Positive and negative sera at a dilution of 1:40 
were incubated with RINmSF cells as described in the cell 
IRMA procedure above. The tracer was incubated for 2 hours. 
A subsequent study was performed to assess the optimum tracer 
incubation time, using positive and negative sera at 1:40 
dilution again. The sample incubation timing used was that 
derived from the previous experiment.
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Non-specific Binding Study
The RINmSF cells used in the cell IRMA are an 
insulin-secreting rat tumour cell line. Insulin
autoantibodies are frequently present in IDDM sera. The ICSA 
positive control serum used in this experiment had been 
screened for insulin autoantibodies (lAA) by an lAA ELISA kit 
(Guildhay Antisera Ltd, Surrey UK), and found to be positive. 
It was necessary to determine whether positive binding in the 
radioassay was due to serum insulin antibodies cross-reacting 
with cellular insulin. A binding-inhibition study was 
performed by incubating the ICSA positive sera with human 
insulin (Humulin) (Eli Lilly, Indiana, USA) overnight at 4 “C. 
The final dilution of the ICSA positive serum was 1:10 and 
the final concentration of the human insulin was BnM. The 
binding of this serum to the RINmSF cells was compared with 
that of untreated positive control serum. A non-diabetic 
pooled control serum was also included in the assay.
Calculations of Assay Precision and Reproducibility
The intra- and inter- assay coefficients of variation 
for the optimized assay, were calculated. The coefficients 
of variation (CV) were calculated according to the formula:
CV = SD X 100%
where SD = Standard Deviation 
X = mean of values
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Intra-assay Precision of Cell IRMA
The intra-assay coefficient of variation was calculated 
for 10 relpicate samples of a positive control serum, at 1:20 
d ilution.
Inter-assay Reproducibility of Cell IRMA
The inter-assay coefficient of variation was calculated 
for three sets of 8 replicate serum samples, at 1:20 
d i luti o n .
3.2.2 Enzyme-linked Immunosorbent Assay
Initial ELISA Protocol
The use of cell surface antigens from target cells, 
coated onto microtiter plates, would enable the development 
of more reproducible assays for ICSA that are more specific 
and simpler to perform. The following section describes the 
development of a rapid ELISA for ICSA. All samples were 
assayed as duplicates in the ELISA.
1)Islet cell membrane antigens were coated onto 
medium-binding polypropylene microtiter plate wells (Nunc, 
Roskilde, Denmark) by adsorption at pH 7.4. The RINm5F 
membrane preparation was diluted 1/100 in phosphate buffered 
saline PBS (protein estimated approximately 50pg/ml) and the 
microtiter plates were incubated with 200pl of this solution 
per well for 2 hours at room temperature. The plates were 
washed four times with PBS and the wells were then blocked by 
incubation with a solution of normal donkey serum (1/50) 
(Guildhay Antisera Ltd) in PBS for 30 minutes at room 
temperature. The plates were washed four times with PBS
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containing 0.1% (w/v) gelatin (BDH Chemicals Ltd, Dorset, UK)
and 0.05% (v/v) Tween 20 (PBSGT).
2) Serial dilutions were made of human diabetic and 
pooled normal control serum samples that had previously been 
heat-inactivated and adsorbed against rat liver powders 
(Sigma, St Louis, USA). The samples were incubated for 60 
minutes at 37*C and the plates were washed four times with 
PBSGT.
3) Horseradish peroxidase-conjugated affinity-purified 
sheep anti-human IgG (Guildhay Antisera, Guildford, UK) was 
incubated at 1:10,000 for 30 minutes at 37°C and washed out 
four times with PBSGT.
4) The colour reaction was produced using the substrate 
tetramethyl-benzidine TMB (Aldrich, Milwaukee, USA) and 
hydrogen peroxide. The substrate solution was prepared by 
adding 10 mg TMB and 40 pi hydrogen peroxide (20 volume) to 
100 mis of citrate-phosphate buffer pH 5.0. This was made up 
fresh for each assay and 150 pi was added to each well and 
incubated for 30 minutes at 37*C. The reaction was stopped 
by the addition of 50 pi 2.5M H_aO* to each well. Optical 
density readings were made at 450nm using a Titertek 
Multiskan ELISA reader (Flow Laboratories). Statistical 
significance of differences for results obtained, were 
calculated by the Student's t-test.
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Optimization of ELISA
A series of studies were performed to determine the 
optimum concentration of reactants and incubation periods 
that would give the highest positive and lowest negative 
signals.
Antigen Concentration and Coating Times
Various dilutions of membrane preparation were coated 
onto the microtiter plates: 1/100, 1/1000 and 1/10,000.
These dilutions were made in PBS and 200p1 were incubated per 
well for 2 hours at room temperature. The optimum coating of 
membrane antigens was determined by incubating previously 
determined positive and negative controls at constant 
dilutions. Both ICSA positive and negative control sera were 
incubated in duplicate at 1/10 dilution for 60 minutes at
37*C and the subsequent assay steps were performed as
described in the ELISA procedure.
Sample incubation time
Positive and negative control sera were assayed at 1:10 
dilution and incubation times used were: 15, 30, 60, and 120 
minutes. All the other assay steps were performed as
described in the ELISA procedure.
Calculations of Assay Precision
In order to assess the reliability of the optimized 
assay, the intra- and inter- assay coefficients of variation 
were calculated. The coefficients of variation (CV) were 
calculated according to the formula:
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CV = SD X 100%
where SD = Standard Deviation 
X = mean of values
ELISA Intra-assay Precision and Inter-assay
Reproduc ibility
The intra-assay coefficient of variation was calculated 
for 36 relpicate samples of a positive control serum, at 1:50 
dilution. The inter-assay coefficient of variation was 
calculated for three sets of 12 replicate samples, at a 1:50 
d iluti o n .
Long-term storage of coated microtiter plates
The stability of a coated microtiter plate after one 
week of storage at 37°C is equivalent to storage of that 
coated plate for one month at 4'C. Six microtiter plate 
strips (Nunc, Roskilde, Denmark) coated with RINm5F cell
membrane antigens were stored at 37*C and tested for 
stability at weekly intervals. Dilution curves of positive 
and negative control sera were compared for the six stored 
strips and freshly coated microtiter strips.
Cross-reactivity studies
Cross-reactivity of the islet cell membrane antigens 
(ICMA) with other autoimmune sera were assessed by binding 
studies against human sera containing autoantibodies to
various tissues. Human autoimmune sera to thyrog1obu1in,
thyroid microsomes, gastric parietal cell, mitochondria, and
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epidermal basement membrane were obtained from Dr. Milford 
Ward, (Royal Hallamshire Hospital, Sheffield, UK). Human 
anti-insulin antisera were obtained from Guildhay Antisera 
Ltd, Guildford, UK. Cross-reactivity studies of the ICMA 
against insulin antibodies were also performed by incubating 
with various dilutions of guinea pig polyclonal anti-insulin 
and murine monoclonal anti-insulin antibodies (Guildhay 
Antisera, Guildford, UK). Following a 30 min incubation at 
37°C, the bound immunoglobulins were detected by the addition 
of peroxidase conjugated to affinity purified anti-human IgG 
(1:15,000) or anti-guinea pig IgG (1:300) or anti-mouse IgG 
(1:10,000) (Guildhay Antisera, Guildford, UK).
Assay of ICSA in diabetic sera using rapid ELISA
Serum samples were collected from 32 recently diagnosed
Type 1 (insulin-dependent) diabetic patients and were
screened for the presence of islet cell antibodies using the 
rapid ELISA. These samples had also been screened for ICSA 
by the whole cell IRMA of section 3.2.1 and for cytoplasmic 
islet cell antibodies (ICCA) by indirect immunofluorescence 
staining (Bottazzo & Gleichmann, 1986) (ICCA were assayed at 
the Department of Immunology, Middlesex Hospital, London). 
20 non-diabetic control sera were also tested in parallel. 
Antiserum dilution curves in the ELISA were made using 1:5, 
1:10, 1:50, 1:500, and 1:5000 dilutions of sera. In both the
cell IRMA and the ELISA, samples were termed positive' if
the mean value of the sample assayed at 1:20 dilution, was
greater than 2 standard deviations from the mean of the
negative samples assayed. All the assay results, indirect 
immunofluorescence, cell IRMA, and ELISA were compared.
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Binding Studies of Monoclonal Antibodies in ELISA 
Recently, a study was undertaken to produce 
anti-anti-idiotypic antibodies against islet cell membrane 
antigens (Moyle etal,19BB). Immunoglobulins were precipitated 
from the sera of a diabetic patient with islet cell 
autoantibodies. The immunoglobulins were immunized into 
balb/c mice. Cell fusion between splenocytes from the mice 
and mouse myeloma Sp2 cell line was performed using 
polyethylene glycol as fusogen. 137 murine hybridoma clones 
were derived and their supernatants were screened against 
various antigens including RINm5F cell membranes, using a 
nitrocellulose dot blot system. A series of ten cell lines
(nine secreting IgM, one secreting IgG) were found to bind 
only RINm5F cell membranes. Of these ten antibodies, two 
demonstrated strong immunoperoxidase staining of islet cells 
in paraffin sections of human pancreas, and one of these two 
antibodies was found to fix complement on viable RINmSF
cel Is.
Hybridoma cell lines secreting the anti-anti-idiotypic
antibodies were propagated in balb/c mice. Female balb/c
mice (6-10 week old) were immunosupressed by a single
intraperitoneal injection of 0.3ml pristane
(2,6,10,14-tetramethyl pentadecane; Sigma, St Louis, USA). 
After one week, approximately 5 x 10<^  hybridoma cells in a 
small volume (100-500pl) of serum-free RPMI-1640 medium were 
injected into the peritoneal cavity of each mouse. After
10-14 days animals with ascites tumours were sacrificed,
ascitic fluid removed and centrifuged (300g, 10 mins),
(benchtop centrifuge, MSE Ltd, UK) to remove cells. Ascites 
fluid was preserved with sodium azide (0.1% final
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concentrât ion).
Binding and displacement studies in the ICSA-ELISA were 
performed with one of the monoclonal antibodies 55D2 (IgM) 
that demonstrated immunoperoxidase staining of islet cells in 
paraffin sections. Ascites fluid of 55D2 and a control 
ascites, were diluted (1:5, 1:50, 1:500, 1:5000) and assayed
by the ELISA. Following a 30 min incubation at 3 7 “C, the 
bound immunoglobulins were detected by incubation (37*C, 30 
mins) with peroxidase conjugated to affinity purified 
anti-mouse immunoglobulin (1:1000), (Guildhay Antisera, 
Guildford, UK).
Ascites of the monoclonal antibody 55D2 was incubated 
with dilutions of an ICSA positive control in the ELISA, to 
investigate the displacement of ICSA binding in the assay.
The final dilutions of ICSA positive control were 1:10, 1:20,
1:50, 1:500, 1:5000, and 55D2 ascites was incubated with each
serum dilution at final dilutions of 1:2 and 1:50. These 
were assayed in the optimized ELISA.
Binding-inhibition studies with affinity-purified ICMA
On the basis that the murine monoclonal anti-anti-idiotypic 
antibody 55D2 demonstrated immunoperoxidase staining of islet 
cell membranes, immunoglobulins from the mouse ascitic fluid 
were prepared by precipitation with polyethylene glycol and 
were linked onto activated glass beads for use in 
affinity-purification studies. In a preliminary experiment, 
immunoglobulins were precipitated (by 67. polyethylene glycol) 
from 2 mis of ascitic fluid, and diluted to 10 mis in PBS 
containing 0.027. sodium azide (this final solution contained
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approximately 5mg protein). This solution was mixed with 1 
gram of activated porous glass beads (Guildhay Antisera Ltd) 
and the glass beads were washed twice with 20 mis PBS by
centrifuation (2000g, 5 mins). The beads were then mixed 
with 20 mis of a solution of 17. polyethylene glycol 6000 in 
PBS and rolled for one hour at room temperature. Finally, 
the beads were washed twice by centrifugation (2000g, 5 mins) 
with 20 mis of PBS and were stored in PBS containing 0.027. 
sodium azide at 4*C.
The glass beads were packed into a 10 x 1 cm column.
0.5ml of the RINm5F membrane preparation were allowed to soak
into the column and left to stand for 5 mins at room 
temperature. The column was then washed with a minimum of 20 
mis of PBS and this buffer' fraction was collected. Bound 
antigens were desorbed and eluted from the affinity column
with O.IM glycine-HCl pH 2.2, and 4 x 5 ml fractions of this
were collected and each fraction neutralised with lOOpl of 2M 
Tris HCl buffer, pH 7.5-8.0. These eluted samples were all 
dialysed against PBS containing 0.027. azide overnight at 4 “C. 
The affinity column was washed thoroughly with PBS containing
0.027. sodium azide until the pH returned to 7.4. The column
was stored at 4 "C until further use. The buffer fraction and 
the first eluted fraction were used in binding-inhibition 
studies in the ELISA. Dilutions of an ICSA positive control 
(1:10, 1:50, 1:500, 1:5000 final dilutions) were each
preincubated with 1:2 dilutions of the buffer and first
eluted fractions (37“C, 30 mins). Untreated dilutions of 
positive control were also incubated at 37"C for 30 mins. 
These samples were then assayed in the optimized ELISA.
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3.3 RESULTS
3.3.1 Cell IRMA
Serial dilutions of 32 recently diagnosed IDDM samples 
were assayed in the cell IRMA. Two of the positive sera 
obtained are described in fig 3.1. The control serum shown 
in fig 3.1 was a pooled normal human serum, and produced a 
background binding of 2000 + 200 cpm at 1:10 dilution. With 
double dilution, the background signal reduced slightly to 
1500 + 200 cpm at 1:160 dilution. The dilutions of the 20 
non-diabetic control samples showed mean (n=20) values 
similar to those of the pooled normal serum. The two 
diabetic sera described produced strong binding signals 
between 1:10 and 1:80 dilution. The stronger of these, D58 
was used as a positive control in the optimization studies. 
All of the diabetic sera and a pooled non-diabetic serum were 
tested for binding to mouse myeloma NSl, and mouse 3T3 cells. 
All sera showed binding similar to that of normal control in 
the RINmSF cell IRMA.
Optimization of cell numbers
Cell numbers were diluted in the radioassay with 
positive control serum at 1:20 dilution. The cell number per 
tube that gave the highest positive signal and the lowest 
negative signal was 20 x 10^ cells per tube (fig 3.2). The 
binding of the positive control decreased dramatically with 
dilution of cell numbers from 2.5 x 10= cells (9700 +1000cpm) 
and less, and the negative control signal increased with 
increasing cell numbers.
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Fig 3.1 Assay of ICSA in IDDM sera by the Cell IRMA. 
Dilutions of IDDM sera D58 (•) and D20 (^) and pooled 
control serum from normals (O) were assayed.
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Fig 3.2 Optimization of cell numbers used in the Cell 
IRMA. Positive (•) and pooled negative (O) sera were 
assayed at 1:20 dilution with varying numbers of RINmSF 
cells. The optimum range of cell nmbers per assay tube 
was 10-20 X 10'"'.
m
o
S
TJ
§
S
>»
■P•H
>•H
1
I
14.0
12.0
10.0
.0
.0
0
.0
0
0.625 2.5 10.0 40.020.0 80.0
Number of Cells per tube (xlO^)
page 123
Optimization of sample and tracer incubation
The optimum sample incubation time was determined by 
assay of positive and negative controls with varying 
incubation times and constant tracer incubation time. The 
optimum sample incubation was 60 mins giving the highest 
positive (7000 + 500 cpm) and lowest negative (2000 + SOOcpm) 
signals (fig 3.3). The optimum tracer incubation time was 
determined by using positive and negative controls incubated 
with cells for 60 mins (determined in the previous 
experiment), and various tracer incubation timings (fig 3.4). 
The optimized tracer incubation time was 60 mins.
Insulin Competition Study
The ICSA positive serum (found to have insulin 
antibodies) was incubated with human insulin at 8 mM final 
concentration overnight 4*C. There was no significant effect 
on binding of the positive serum in the cell IRMA (fig 3.5), 
suggesting that the possible non-specific binding of insulin 
antibodies to rat insulin in the cells was not significant.
Precision and Reproducibility for Ceil IRMA
The intra-assay coefficient of variation was 87. (n=10),
and the inter-assay coefficient of variation was 157. (n=24)
for the optimized assay.
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Fig 3.3 Optimization of sample incubation time. 
Positive (•) and negative <0) serum controls were assayed 
with varying incubation times and a constant tracer time of 2 
hours. Optimum sample incubation time was 60 mins at 37'C.
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Fig 3.4 Optimization of tracer incubation time.
Positive (•) and negative ( O ) controls were assayed by 
incubation with RINmSF cells for 60 mins and tracer 
incubation was varied. Optimum tracer incubation time was 60 
mins at 37"C.
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Fig 3.5 Effect of insulin on binding of positive 
control to RINmSF cells. Untreated positive control (•) and 
positive control incubated with 8 mM human insulin (▼) were 
assayed in the radioassay. Pooled negative control serum (O) 
was also included.
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3.3.2 ELISA
Dilution curves were obtained using serum -from a
diabetic patient that had been screened positive -for ICSA by 
the cell IRMA, and positive for ICA by the indirect
immunofluorescence assay. A pooled control serum from normal 
subjects was used as the negative control. At 1:10 dilution, 
the positve serum showed an 00 of 1.0 + 0.05 compared with an 
OD of 0.2 + 0.05 for the negative control (fig 3.6).
Statistical differences between positive and normal controls 
were obtained up to a dilution of 1:300 (p < 0.01).
Optimization of ELISA
Coating of membrane antigens
RINm5F membrane preparation was diluted 1:100, 1:1000,
and 1:10,000 and the binding of the positive and negative
controls determined (fig 3.7). The optimum dilution that
gave the highest positive and lowest negative signals was 
1:1000 dilution of membrane preparation. This dilution was 
equivalent to a whole cell concentration of 10 x 10^ cells 
per well (cf. the cell binding radioassay), which was very 
comparable to the optimum cell number derived for the cell 
IRMA (fig3.2).
Sample incubation time
The sample incubation time was optimized to 30 minutes. 
This incubation time produced a high positive to negative 
signal at a serum dilution of 1:10. In this study, as the 
incubation time was increased, the negative signal was found 
to rise from OD 0.25 + 0.05 at 30 mins, to OD 0.35 + 0.04 at 
120 mins (fig 3.8).
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Fig 3.6 Binding in ICSA ELISA of ICSA positive control 
previously determined by cell-binding radioassay. Dilutions 
of positive control (A) and pooled negative control (•) were 
assayed.
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Fig 3.7 Optimization of RINmSF membrane antigens coated 
to microtiter plate wells. Positive control (•) and negative 
control ( O ) sera were incubated in microtiter strip wells 
pre-coated at varying concentrations of RINmSF membrane 
antigens. Optimum membrane dilution obtained was 1:1000.
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Fig 3.8 Optimization of sample incubation time in 
ELISA. Positive control (•) and negative control (O) samples 
were incubated at 1:10 dilution for different times in the 
ELISA. Optimum sample incubation time was 30 mins at 37*0.
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Cross Reactivity
No significant cross-reactivity in the assay was 
observed with human autoantibodies to gastric parietal cells, 
mitochondrial and epidermal basement membranes. However, the 
human serum positive for thyroglobulin antibodies showed an 
OD of 0.38 at a 1:5 dilution, indicating the presence of some 
islet cell antibodies (fig 3.9). No binding was observed 
with the human anti-insulin control. Cross-reactivity of the 
assay against insulin antibodies was also performed using a 
guinea pig anti-insulin (titre 1:25,000) and a murine 
monoclonal anti-insulin (titre 1:10,000). No cross-reactions 
were observed with either antibodies (fig 3.10).
Assay Precision and Reproducibility of ELISA
The intra-assay variation was 6% (n=36) and the
inter-assay coefficient of variation was 97. (n=36) .
Anti-anti-idiotypic monoclonal antibody displacement study
Dilutions of ascites of the monoclonal antibody 55D2 in 
the optimized ELISA, showed a binding curve that was very 
similar to that obtained for the ICSA positive control in 
figure 3.11. The control ascites tested in the same assay 
showed similar binding to that of normal serum.
The monolconal antibody 55D2, when incubated in the
ICSA-ELISA was found to displace the binding of the human 
positive control serum (fig 3.11) at 1:2 and 1:50 dilutions 
of ascitic fluid from balb/c mice injected with these cells. 
These data suggested that 55D2 recognised an islet cell
membrane antigen that the ICSA positive diabetic serum was
binding to.
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Affinity-purified ICMA displacement study
Affinity-purified antigens from islet cell RINmSF 
membranes were used in a competition study with an ICSA
positive control (fig 3.12). The first eluted fraction was
found to displace binding in the ELISA. The second eluted
fraction displaced binding to a lesser extent than the first 
fraction (not shown in figure). The buffer fraction was also 
found to displace binding to a small degree. This was
probably due to overloading of the affinity column (i.e. 
excess unbound antigens were present in the initial buffer 
wash).
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Fig 3.9 Cross-reactivity study in ELISA.
Human sera assayed were:
Positive control (‘^)
XI - Thyroglobulin autoantibody control (■)
X2 - Gastric Parietal cell autoantibody control (x)
X3 - Mitochondrial autoantibody control (♦)
X4 - Epidermal basement membrane autoantibody (•)
X5 - Insulin autoantibody control ( A )
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Fig 3.10 Insulin antibody cross-reactivity study in 
ELISA.
ICSA positive control )
Murine anti-insulin monoclonal andtibody
(titer 1:10,000) (□). Guinea pig polyclonal insulin
antibody (titer 1:25,000) (*).
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Fig 3.11 Displacement study in ELISA, with islet cell 
binding monoclonal antibodies. Monoclonal antibody 5502 was 
incubated at 1:2 (O) and 1:50 (□) with an ICSA positive
control ( • ). Untreated ICSA positive control was also 
assayed. At similar dilution points, ascites of 5502 showed 
a dilution curve similar to that of the ICSA conrtol in this 
experiment. At 1:2 and 1:50 dilutions 5502 caused significant 
displacement of ICSA binding.
1.4 _
I
s
> s
■p•H
COI
COo•H
P
o
1.2 -
1.0
0.8
0.6 —
0.4 _
0.2
I 1-------- 1-----
1:10 1:20 1:50
I- - -
1:500
Serum Dilution
 r
1:5000
page 136
Fig 3.12 Displacement study in the ELISA with affinity 
purified RINmSF membrane fractions. Affinity purified 
fraction 1 (^) and buffer wash fraction (■> were preincubated
with ICSA positive control (•) and binding assayed for in the 
ELISA.
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Tab le 3.1 Correlation between ICCA and ICSA assays.
SAMPLE ICA-IgG ICA-CF ICSA-IRMA ICSA-ELISA
2 +w +w + +
3 -
6 +w -
Y + + + + +
3 +  +  +  +
9 + +w +* + +
10 +w + -
11 -  _  +  +
12 -
13 -
14 -  -  -
15 -
16 -  +  +
2 "y — — — +
18 +w +w -
19 -  -  +  +
20 —  —  4- +
21 -  -
22 -  _  _  -
23 -
24 —  —  —  —
25 -  -
26 +  +
27 +w - + +
28 - -  -
29 -  -  -  -
30 -  -  -
58 + +  + + + + +
63 + + + +
+ Positive 
+w Weakly Positive 
++ Strongly Positive 
Negative
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3.4 DISCUSSION
The above study describes the development of two assays 
for ICSA : a cell-binding immunoradiometric assay, and a
rapid ELISA for the routine quantitation of ICSA in sera from 
IDDM and prediabetic patients. The insulin-secreting rat 
cell line RINmSF was used to provide the target antigen(s) in 
both assays. A low-secretor cell line was used in order to 
reduce the possible nonspecific binding due to insulin.
The IRMA was optimized such that 20 x 10=^  cells were 
used per assay tube (fig 3.2) and the sample and tracer
incubations were 60 mins each (figs 3.3 and 3.4). Some 
initial validation studies were performed to demonstrate that 
insulin autoantibodies present in the ICSA positive sera did 
not contribute significant nonspecific binding (fig 3.5). A
series of 32 recently diagnosed IDDM serum samples were
assayed by this radioassay and the positive controls were 
used in the development of the ELISA for ICSA.
The ELISA for ICSA was developed using polypropylene
microtiter plates that were pre-coated with islet cell
membrane antigens (ICMA). The ELISA could be completed
within 1 hr, using a 30 minute sample incubation time (fig 
3.8). The long-term stability of these ICMA pre-coated 
plates was in excess of 6 months when stored dry at 4"C. 
This represented a significant saving in time and permited
large batches of plates to be pre-coated in order to reduce
batch to batch variations in the assay.
ICSA-ELISA dilution curves were obtained from sera of 
recent-onset IDDM patients (heat-inactivated and adsorbed
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against rat liver powders), which had been screened positive 
for ICCA by the indirect immunofluorescence technique, as 
well as positive for ICSA by the cell-binding IRMA developed 
in section 3.2.1. No significant cross-reactivity was 
detected with other human autoantibodies tested (fig 3.9). 
The rat cell line RINm5F is an insulin-secreting line derived 
from a transplantable rat insulinoma. A low-secretor cell 
line was derived from the original line, and cell membranes 
were prepared from this to coat the polypropylene microtiter 
plates. A low secretor was selected in order to minimize the 
possiblity of contamination of the membrane antigen
preparation with insulin. Anti-insulin antibodies are often 
detected in the sera of diabetic patients and so it was
important to assess the cross-reactivity due to possible 
contaminating insulin adsorbed to the microtiter plates. 
This was assessed by binding studies using various 
anti-insulin antibodies: human and guinea pig polyclonal, and
a murine monoclonal (fig 3.10). Insulin antibodies had
previously been detected by ELISA in the sera from newly
diagnosed IDDM patients used in this study. Thus, the
insulin antibody cross-reactivity studies confirmed that the 
binding was not due to insulin antibodies. Subjects who have 
insulin antibodies as well as islet cell antibodies present 
in their sera are thought to be at higher risk of developing 
diabetes mellitus (Better le et al,1987), and so the low 
cross-reactivity of insulin antibodies in this assay makes 
the assay a more specific and potentially useful tool for the 
detection of islet cell surface antibodies.
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The preliminary data here suggest a good correlation 
between the ICSA-ELISA and the ICSA cell-binding IRMA. The
results of these two assays were also compared with those for
cytoplasmic ICA screened by indirect immunofluorescence on 
frozen pancreatic sections (Table 3.1). Thirteen IDDM
patient sera (40.6%) were positive in both the ICSA-ELISA and
the cell IRMA. Only one sample was positive in the ICSA-IRMA 
but not in the ICSA-ELISA, and only one sample was positive 
in the ICSA-ELISA but not in the IRMA. Ten samples (31%) 
were positive for cytoplasmic ICA and also (with the 
exception of one sample) positive for complement-fixing ICA. 
Six samples were positive for all four of the assays. The 
incidence of ICSA by these assays is comparable to data (32%) 
obtained previously (Lernmark et al, 1978). It is thought 
that the relatively low incidence of ICSA in recent-onset 
IDDM sera are due to falling titers of these autoantibodies. 
This might be expected if ICSA are directly pathogenic to the 
islet cell surface, and precede the onset of IDDM and ICCA. 
The incidence of ICCA in the diabetic samples in the present 
study was lower than previously reported results (60% and up 
to 90%). The reasons for this are not clear. However, it is 
known that standardization studies for the indirect 
immunofluorescence assay have been necessary to reduce 
inter-laboratory variations in results.
A larger study is being undertaken to further evaluate 
the ICSA-ELISA. Work is also currently in progress to fully 
characterize the islet cell membrane antigen(s).
In conclusion, this study describes two assays for ICSA. 
Radioassays, immunofluorescence assays and ELISAs using whole
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cells, -for the detection of ICSA have been in existence for 
some years. However, the development of a rapid and simple 
ELISA assay that is suitable for the routine screening of 
sera from IDD patients, provides distinct advantages over the 
existing whole cell assays. The preparation and storage of 
the coating antigens may be quantified reliably and thus 
obviate the technical problems associated with using whole 
cells attached to microtiter plates. Together with insulin 
antibody assays, the method is also suitable for the large 
scale screening of individuals at high risk of developing 
Type 1 insulin-dependent diabetes (Better le et al,1987). The 
ICSA-ELISA also has an obvious application in the screening 
of monoclonal antibodies that are secreted by hybridomas in 
tissue culture. The culture and screening of large numbers 
of hybridoma clones is a major undertaking and thus the 
existence of rapid and specific screening assays is 
important. The ICSA-ELISA may be a suitable tool for such 
wor k.
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CHAPTER 4: FINAL DISCUSSION AND CONCLUSIONS
Production of Human Monoclonal Antibodies -from
Lymphocytes of a Diabetic Patient
Over a decade has passed since the initial detection of 
humoral islet cell antibodies in the sera of Type 1 diabetic 
patients. There is now overwhelming evidence that Type 1 
(insulin-dependent) diabetes mellitus is a complex syndrome 
of disorders, involving complex autoimmune phenomena (Drell 
and Notkins, 1987). Certain immunological and immunogenetic 
evidence suggesting that Type 1 diabetes was an "autoimmune" 
disease, was discovered even before humoral autoantibodies 
staining the pancreatic islet cells, were demonstrated in the 
sera of diabetics with polyendocrine disorders (Bottazzo et 
al, 1974; MacCuish et al, 1974). The fact that diabetics may 
also exhibit autoimmune endocrinopathies, characterized by
autoimmunity to a number of organs, has raised questions
about the aetiology of autoimmune diseases. The reasons for 
this multiple endocrine autoimmunity and the nature of the
pathogenetic processes involved in the development of IDDM, 
are still obscure.
The fact that there is a clear association between IDDM 
and other autoimmune endocrinopathies suggests common
pathogenetic mechanisms for these disorders. It is possible 
that a common pathogenesis involves a particular group of 
antigenic determinants. A principal issue has been to 
determine the nature of autoantigens being targeted, and 
whether they are predominantly organ-specific or common to 
various endocrine tissues. Despite the preliminary
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identification of common antigens existing on several 
endocrine tissues as an explanation for multiple organ 
immunoreactiVity, (Satoh et al,1983; Garzelli et al,1986),
there is poor understanding about their pathogenic relevance.
It is probable that diabetes mellitus has an aetiology 
that involves a number of factors, of which a genetic 
predisposition towards the development of autoimmune 
phenomena, and some chemical or viral trigger are key
components. It is conceivable that a specific group of cell
surface antigenic determinants are also involved in the
mediation of autoimmune attacks. It has also been suggested 
that the aetiology may involve some kind of dysfunction in 
the regulation of the immune system (Cahill and McDevitt,
1981). An immunological status of this kind might be easy
prey to some trigger, mediated by specific antigens and
resulting in autoimmunity against specific endocrine tissues.
The development of hybridoma techniques (Kohler and
Milstein, 1975) has provided an extremely important tool to 
immunological research. The technique has made possible the 
immortalization of B- 1ymphocytes and subsequent culture of 
clones of hybridoma cells that secrete antibody of single 
specificities. Since such cell lines may secrete these 
immunoglobulins indefinitely, the technique has provided a 
means of generating theoretically unlimited quantities of 
specific antibodies. Since its initial development by Kohler 
and Milstein, the hybridoma technique has been exploited for 
a variety of applications.
The immune response of an animal produces a polyclonal
page 145
mixture of antibody molecules that may have specificities to 
different epitopes on the same molecule. Because hybridoma 
techniques enabled the immortalization and cloning,of single 
B-cell specificities, it was therefore possible to dissect 
the "polyclonal" immune response into its constituent
"monoclonal" specificities. This facet of the technique 
lends itself to the study of autoimmunity where the precise 
nature of the autoantigens being targeted are not known. In 
autoimmune diseases to endocrine tissues, there are
frequently associations of autoantibodies to a variety of 
tissues. It is likely that these mu 11ip1 e-organ reactive
phenomena are due to the polyclonal nature of the humoral
autoantibodies. The hybridoma technique provides a means of 
identifying and studying the specificities of individual 
autoreactive cells.
The aim of the study described in chapter 2 was to 
investigate whether mu11ip1 e-organ autoimmunity associated
with insulin-dependent diabetes involved commonly shared 
autoantigens on different tissues, or whether the autoimmune
response was a complex mixture of different organ-specific
autoantibodies. The issue of commonly shared autoantigens 
has been investigated previously (Satoh et al,1983; Garzelli 
et al,1986). These workers derived several hybridomas from 
patients with multiple autoimmune endocrinopathies. These 
were shown to secrete human monoclonal antibodies that 
cross-reacted with antigens present on various endocrine 
organs. Their studies demonstrated the existence of multiple 
organ-reactive autoantibodies that implied the existence of 
antigens common to different endocrine tissues. The
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pathogenetic significance of such autoantibodies is still 
unclear, and their existence provides only one explanation 
for multiple organ-reactivity since mixtures of
organ-specific autoantibodies may also be present in such 
patients.
In the present study, peripheral blood lymphocytes from 
a patient with acute onset diabetes mellitus, islet cell 
antibodies, thyroid microsomal and thyroglobulin
autoantibodies, were fused with the murine myeloma cell line 
P3-NS1/1-AG4-1. Following the successful culture and cloning 
of human heterohybridoma cells, a panel of human monoclonal 
autoantibodies were generated. Two of the monoclonal 
autoantibodies generated were found to react with human 
thyroid antigens. Monoclonal antibody HML3.22 identified an 
epitope on the TSH receptor of thyroid epithelium, and 
monoclonal antibody HML3.21 identified a component of 
thyrog1obulin.
Regarding the issue of multiple organ autoimmunity in 
disorders such as Type 1 diabetes, the results of this study 
demonstrate the occurrence of organ-specific autoantibodies 
in association with the disorder. Monoclonal antibody 
HML3.22 was screened by immunohistochemica 1 staining against 
a variety of normal human tissues including nonendocrine 
tissues, and was found only to react with thyroid epithelial 
cells in frozen and paraffin wax sections. Similarly, 
HML3.21 was found to react only with thyroglobulin.
The culturing of human heterohybridomas is hindered by 
technical difficulties due to the chromosomal instability of
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these constructs. For this reason and also because somatic 
cell hybridization is an inefficient and random process, a 
limited number of autoreactive clones were derived. It is 
thus possible that multiple organ-reactive clones of B-cells 
also existed amongst this patient's spectrum of autoreactive 
cells. Nevertheless, this study provides suporting evidence 
that multiple organ reactivity in diabetes involves
organ-specific autoantibodies.
The results of this study demonstrate the complexity of 
the autoimmune response that may be associated with 
insulin-dependent diabetes mellitus. It raises questions 
about the aetiology of autoimmune phenomena and the
pathogenetic relevance of autoantibodies to other endocrine 
t i ssues.
Development of Assays for Islet Cell Surface Antibodies
Since the aim of the study in chapter 2 was to
immortalize B-lymphocytes from a diabetic patient,
irrespective of the immune specificities of resulting
hybridomas, the first-line screen was a solid-phase
immunoradiometric assay for human immunoglobulin. The
pathogenic relevance of islet cell autoantibodies is of
particular importance in the study of autoimmunity in Type 1 
diabetes mellitus. Thus, the aim of the study described in 
chapter 3 was to develop rapid assays for islet cell surface
antibodies in IDDM sera. Such assays could also be used to
screen hybridoma supernatants. This would make the screening 
procedure and identification of islet cell-reactive clones 
more efficient than was possible in the previous study.
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Islet cell antibodies are strongly associated with 
insulin-dependent diabetes, and although a pathogenic role 
for these autoantibodies is not yet established, their 
presence has been shown to precede the onset of disease. In 
vitro studies have demonstrated the existence of cytotoxic 
islet cell surface antibodies in the sera of Type 1 diabetic 
patients. The nature of the islet cell autoantigens are 
poorly understood and considerable efforts have already been 
made towards their characterization.
The accurate detection of islet cell antibodies is of 
diagnostic and clinical importance. The existing screening 
systems for ICCA and ICSA involve the use of tissue targets 
such as human pancreatic sections or whole pancreatic cells. 
Autoantibodies that are detected with these systems may 
assist in the subsequent purification of the specific 
autoantigens from those tissues. The aim of the study 
described in chapter 3, was to develop assays for islet cell 
surface antibodies, that would provide certain advantages 
over existing assays.
The cell IRMA made use of iodinated sheep second 
antibodies to human IgG or IgM instead of iodinated protein-A 
used in previous assay systems. The iodinated second 
antibodies to human immunoglobulins had been affinity 
purified and were specific for human IgG. Since protein A 
does not bind to certain subclasses of IgG (human IgG3), the 
use of second antibodies to human immunoglobulins was
preferred, and made the radioassay specific for IgG-ICSA.
The ELISA described, involved the use of microtiter 
plates coated with RINm5F cell membrane antigens. The ELISA
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was optimized to be performed using 30 minute incubations of 
samples and enzyme-labelled second antibody at 3 7 “C. The 
stability of these coated plates was found to be in excess of 
six months. The technique showed good intra-assay precision 
(cv=7*/., n = 36) and reproducibility (cv=97., n=36) . The use of 
this ELISA system, avoided the potential problems of 
precision that might be associated with attachment and 
fixation of whole cells to microtiter plates. The ELISA 
showed a good correlation with the cell IRMA, and was a 
suitable tool for the assay of ICSA in serum samples. It 
might also be useful for testing supernatants of hybridomas 
derived from lymphocytes of type 1 diabetic patients.
In terms of future work, the ELISA will be used in 
larger studies of ICSA and their incidence in individuals at 
increased risk of developing diabetes. The assay will also be 
used to determine the persistence of ICSA in recently 
diagnosed insulin-dependent diabetics. The simultaneous 
assay of insulin autoantibodies will provide additional 
information regarding the predictive value of these markers 
in the onset of diabetes mellitus (Better le et al, 1987).
FUTURE WORK
Human hybridoma techniques
The full potential of human monoclonal antibody 
techniques has not yet been realised. This is due to certain 
technical difficulties involved in the construction of stable 
human hybridomas or in the immortalization of stable cell 
lines by alternative means such as Epstein-Barr virus 
transformation. The continued search for suitable fusion
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partners such as heteromyelomas, should eventually solve this 
problem. Improvements in the human hybridoma technology will
enable the continued study of the immune response in
disorders such as Type 1 insulin-dependent diabetes mellitus, 
that involve an autoimmune component. As antigenic
specificities involved in the autoimmune response are
identified and characterized, so will the aetiologic roles of 
these autoantigens be clarified. Such studies should throw 
light on the development of autoimmne diseases involving 
multiple organ-immunoreactivity.
1mmunotherapy
The successful production of human monoclonal 
autoantibodies should also lead to the production of murine 
anti-idiotypic antibodies against them. These reagents may 
have potential use as immunotherapeutic reagents.
Theoretically, the use of human monoclonal antibodies as 
reagents would be preferable to their murine counterparts due 
to the dangers of immune reaction against the murine 
antibodies. As human monoclonal antibody techniques are
developed further, it should also be possible to produce 
human monoclonal anti-idiotypic antibodies against these 
monoclonal autoantibodies.
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